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A B S T R A C T
Background
Infective endocarditis is a microbial infection of the endocardial surface of the heart. Antibiotics are the cornerstone of treatment, but due
to the di&erences in presentation, populations a&ected, and the wide variety of micro-organisms that can be responsible, their use is not
standardised. This is an update of a review previously published in 2016.
Objectives
To assess the existing evidence about the clinical benefits and harms of di&erent antibiotics regimens used to treat people with infective
endocarditis.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase Classic and Embase, LILACS, CINAHL, and the
Conference Proceedings Citation Index - Science on 6 January 2020. We also searched three trials registers and handsearched the reference
lists of included papers. We applied no language restrictions.
Selection criteria
We included randomised controlled trials (RCTs) assessing the e&ects of antibiotic regimens for treating definitive infective endocarditis
diagnosed according to modified Duke's criteria. We considered all-cause mortality, cure rates, and adverse events as the primary
outcomes. We excluded people with possible infective endocarditis and pregnant women.
Data collection and analysis
Two review authors independently performed study selection, 'Risk of bias' assessment, and data extraction in duplicate. We constructed
'Summary of findings' tables and used GRADE methodology to assess the quality of the evidence. We described the included studies
narratively.
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Main results
Six small RCTs involving 1143 allocated/632 analysed participants met the inclusion criteria of this first update. The included trials had a
high risk of bias. Three trials were sponsored by drug companies. Due to heterogeneity in outcome definitions and di&erent antibiotics
used data could not be pooled.
The included trials compared miscellaneous antibiotic schedules having uncertain e&ects for all of the prespecified outcomes in this review.
Evidence was either low or very low quality due to high risk of bias and very low number of events and small sample size.
The results for all-cause mortality were as follows: one trial compared quinolone (levofloxacin) plus standard treatment
(antistaphylococcal penicillin (cloxacillin or dicloxacillin), aminoglycoside (tobramycin or netilmicin), and rifampicin) versus standard
treatment alone and reported 8/31 (26%) with levofloxacin plus standard treatment versus 9/39 (23%) with standard treatment alone;
risk ratio (RR) 1.12, 95% confidence interval (CI) 0.49 to 2.56. One trial compared fosfomycin plus imipenem 3/4 (75%) versus vancomycin
0/4 (0%) (RR 7.00, 95% CI 0.47 to 103.27), and one trial compared partial oral treatment 7/201 (3.5%) versus conventional intravenous
treatment 13/199 (6.53%) (RR 0.53, 95% CI 0.22 to 1.31).
The results for rates of cure with or without surgery were as follows: one trial compared daptomycin versus low-dose gentamicin plus
an antistaphylococcal penicillin (nafcillin, oxacillin, or flucloxacillin) or vancomycin and reported 9/28 (32.1%) with daptomycin versus
9/25 (36%) with low-dose gentamicin plus antistaphylococcal penicillin or vancomycin; RR 0.89, 95% CI 0.42 to 1.89. One trial compared
glycopeptide (vancomycin or teicoplanin) plus gentamicin with cloxacillin plus gentamicin (13/23 (56%) versus 11/11 (100%); RR 0.59, 95%
CI 0.40 to 0.85). One trial compared ceOriaxone plus gentamicin versus ceOriaxone alone (15/34 (44%) versus 21/33 (64%); RR 0.69, 95%
CI 0.44 to 1.10), and one trial compared fosfomycin plus imipenem versus vancomycin (1/4 (25%) versus 2/4 (50%); RR 0.50, 95% CI 0.07
to 3.55).
The included trials reported adverse events, the need for cardiac surgical interventions, and rates of uncontrolled infection, congestive
heart failure, relapse of endocarditis, and septic emboli, and found no conclusive di&erences between groups (very low-quality evidence).
No trials assessed quality of life.
Authors' conclusions
This first update confirms the findings of the original version of the review. Limited and low to very low-quality evidence suggests that the
comparative e&ects of di&erent antibiotic regimens in terms of cure rates or other relevant clinical outcomes are uncertain. The conclusions
of this updated Cochrane Review were based on few RCTs with a high risk of bias. Accordingly, current evidence does not support or reject
any regimen of antibiotic therapy for the treatment of infective endocarditis.
P L A I N   L A N G U A G E   S U M M A R Y
Antibiotic therapy for the treatment of infective endocarditis
Review question
We aimed to assess the existing evidence about the clinical benefits and harms of di&erent antibiotics regimens used to treat people with
infective endocarditis.
Background
Infective endocarditis is an infection of the inner lining of the heart. It is a serious infection that is frequently fatal, and cardiac surgery is
oOen required. Antibiotics are medicines that treat infections and are the cornerstone of treatment for infective endocarditis. Treatment
of patients with infective endocarditis is nosocomial (in-hospital). Despite this, there are surprising di&erences between guidelines in their
recommendations for antibiotic therapy. Furthermore, due to the dose and length of time that antibiotics must be given for, the antibiotics
can have serious side e&ects, such as kidney and ear damage, and cause allergic reactions.
Study characteristics
We identified only six randomised controlled trials (studies in which participants are assigned to one of two or more treatment groups using
a random method) that compared di&erent antibiotic regimens, which included a limited number of participants. Each trial investigated
di&erent types and doses of antibiotics. The included studies were published between 1998 and 2019 and were conducted in the USA,
Spain, Finland, and Denmark. The evidence is up-to-date as of 6 January 2020.
Key results
This first update confirms the findings of the original version of the review. Limited and low to very low-quality evidence suggests that the
comparative e&ects of di&erent antibiotic regimens in terms of cure rates or other relevant clinical outcomes are uncertain. The conclusions
of this updated Cochrane Review were based on few randomised controlled trials with a high risk of bias. Accordingly, the current evidence
does not support or reject any regimen of antibiotic therapy for the treatment of infective endocarditis.
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Quality of evidence
The confidence in the results of this review is low to very low. The included studies had limitations in the way they were designed and
performed, and three studies were sponsored by the manufacturer of the medicine that was assessed. Moreover, the limited number of
people included in the studies led to uncertain results. Larger studies are required to provide more information about the best antibiotic
regimens to treat people with infective endocarditis.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Levofloxacin compared with standard treatment for Staphylococcus aureus endocarditis
Levofloxacin compared with standard treatment for Staphylococcus aureus endocarditis
























ty at 1 year
Follow-up: 28 days








This information was from a trial conducted to
assess bacteraemia by Staphylococcus aureus
(FINLEVO Trial 2006).
Cure 4 See comment See comment Not estimable4 - See comment The trial did not report information on cure.
Adverse events 4 See comment See comment Not estimable4 - See comment The trial did not report information on adverse
events for people with endocarditis.
Congestive heart fail-
ure 4
See comment See comment Not estimable4 - See comment The trial did not report information on conges-
tive heart failure.
Septic embolism 4 See comment See comment Not estimable4 - See comment The trial did not report information on septic em-
bolism.
Need for cardiac sur-
gical interventions 4























































































































































*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Assumed risk was estimated using control risk group.
2Downgraded by one level for risk of bias. Limitations in the trial design and execution.
3Downgraded by two levels for imprecision due to small sample and very low number of events with an impact on the precision of e&ect estimates.
4Data on this outcome were not supplied for participants with endocarditis.
 
 
Summary of findings 2.   Lipopeptide antibiotic (daptomycin) versus aminoglycoside (low-dose gentamicin) plus antistaphylococcal penicillin
(nafcillin, oxacillin, or flucloxacillin) or glycopeptide antibiotic (vancomycin) for Staphylococcus aureus endocarditis
Lipopeptide antibiotic (daptomycin) versus aminoglycoside (low-dose gentamicin) plus antistaphylococcal penicillin (nafcillin, oxacillin, or flucloxacillin) or gly-
copeptide antibiotic (vancomycin) for Staphylococcus aureus endocarditis
Patient or population: people with endocarditis caused by Staphylococcus aureus
Settings: inpatients
Intervention: lipopeptide antibiotic (daptomycin)











































































































































































tality at 1 year 1
Cure
Follow-up: 42 days








This information was from a trial conducted to
assess either bacteraemia or endocarditis by Sta-
phylococcus aureus.




See comment See comment Not estimable - See comment The trial did not report information on conges-
tive heart failure.





See comment See comment Not estimable - See comment The trial did not report information on the need
for cardiac surgical interventions.
Uncontrolled infec-
tion 1
See comment See comment Not estimable - See comment The trial did not report information on uncon-
trolled infection.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Data on this outcome were not supplied for participants with endocarditis.
2Downgraded one level for risk of bias. Limitations in the trial design and execution.
3Downgraded two levels for imprecision due to small sample and very low number of events with an impact on the precision of e&ect estimates.




















































































































































Summary of findings 3.   Glycopeptide (vancomycin or teicoplanin) plus aminoglycoside (gentamicin) compared with beta-lactam (cloxacillin) plus
aminoglycoside (gentamicin) for Staphylococcus aureus endocarditis in drug abusers
Glycopeptides (vancomycin or teicoplanin) plus aminoglycoside (gentamicin) compared with beta-lactam (cloxacillin) plus aminoglycoside (gentamicin) for Sta-
phylococcus aureus endocarditis in drug abusers
Patient or population: people with endocarditis due to Staphylococcus aureus in drug abusers
Settings: inpatients
Intervention: glycopeptide (vancomycin or teicoplanin) + aminoglycoside (gentamicin)
























tality at 1 year












This trial included 246 participants with either bac-
teraemia or infective endocarditis. Therefore, 34














See comment See comment Not estimable - See comment The trial did not report information on congestive
heart failure.


























































































































































See comment See comment Not estimable - See comment The trial did not report information on uncon-
trolled infection.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded one level for risk of bias. Limitations in the trial design and execution of trial.
2Downgraded one level for imprecision due to small sample and very low number of events with an impact in the precision of the e&ect estimates.
3Assumed risk was estimated using control risk group.
 
 
Summary of findings 4.   Beta-lactam (ceIriaxone) plus aminoglycoside (gentamicin) versus beta-lactam (ceIriaxone) for infective endocarditis due
to penicillin-susceptible streptococci
Beta-lactam (ceftriaxone) plus aminoglycoside (gentamicin) versus beta-lactam (ceftriaxone) for infective endocarditis due to penicillin-susceptible streptococci
Patient or population: people with infective endocarditis due to penicillin-susceptible streptococci
Settings: inpatients
Intervention: beta-lactam (ceftriaxone) + aminoglycoside (gentamicin)
Comparison: beta-lactam (ceftriaxone)
Illustrative comparative risks* (95%
CI)
Assumed risk Corresponding risk
Outcomes











All-cause mortality during hos-
pital stay and all-cause mortali-
ty at 1 year
See comment See comment Not estimable - See comment The trial did not report informa-
tion on all-cause mortality.
Cure
Follow-up: 3 months




































































































































































The trial authors considered all
adverse events to be related to
the study drugs.
Congestive heart failure See comment See comment Not estimable - See comment The trial did not report informa-
tion on congestive heart failure.
Septic embolism See comment See comment Not estimable - See comment The trial did not report informa-
tion on septic embolism.
Need for cardiac surgical inter-
ventions
Follow-up: 30 months




















*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded one level for risk of bias. Limitations in the trial design and execution.
2Downgraded one level for imprecision. Limitations due to small sample and very low number of events with an impact on the precision of e&ect estimates.
3Assumed risk was estimated using control risk group.
 
 
Summary of findings 5.   Fosfomycin plus imipenem compared with vancomycin for infective endocarditis due to methicillin-resistant Staphylococcus
aureus
Fosfomycin plus imipenem compared with vancomycin for infective endocarditis due to methicillin-resistant Staphylococcus aureus
Patient or population: people with infective endocarditis due to methicillin-resistant Staphylococcus aureus
Settings: inpatients




































































































































































All-cause mortality during hospital stay
and all-cause mortality at 1 year










































See comment See comment Not estimable - See comment The trial did not report
information on septic
embolism.
Need for cardiac surgical interventions
Follow-up: not stated











See comment See comment Not estimable - See comment The trial did not report
information on uncon-
trolled infection.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.



















































































































































Very low quality: We are very uncertain about the estimate.
1Assumed risk was estimated using the control risk group.
2Spanish (10 sites).
3Downgraded two levels for risk of bias. Limitations in the trial design and execution.
4Downgraded two levels for imprecision. Limitations due to small sample and very low number of events with an impact on the precision of e&ect estimates.
 
 
Summary of findings 6.   Partial oral treatment compared with conventional intravenous treatment of endocarditis on the leI side of the heart (on
native or prosthetic valves) and bacteraemia for Streptococcus, Enterococcus faecalis, Staphylococcus aureus, or coagulase-negative staphylococci
Partial oral treatment compared with conventional intravenous treatment of endocarditis on the leI side of the heart (on native or prosthetic valves) and bacter-
aemia for Streptococcus, Enterococcus faecalis, Staphylococcus aureus, or coagulase-negative staphylococci
Patient or population: people with endocarditis on the leO side of the heart (on native or prosthetic valves) with bacteraemia for Streptococcus, Enterococcus faecalis, Sta-
phylococcus aureus, or coagulase-negative staphylococci
Settings: either inpatients or outpatients
Intervention: partial oral treatment
Comparison: conventional intravenous treatment
Illustrative comparative risks* (95% CI)















All-cause mortality during hospital stay
and all-cause mortality at 1 year
Follow-up: 6 months


































Need for cardiac surgical
interventions












































































































































































*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1Assumed risk was estimated using control risk group.
2Danish (15 sites).
3Downgraded one level for risk of bias. Limitations on the execution of trial. It was an open trial.
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B A C K G R O U N D
Description of the condition
Infective endocarditis is a microbial infection of a native or
prosthetic heart valve, the endocardial surface, or an indwelling
cardiac device (Cahill 2016). The diagnostic criteria include the
combination of clinical, echocardiographic, and microbiological
data, which are known as Duke’s criteria (Baddour 2015). However,
it is accepted that the sensitivity of the Duke classification is not
optimal, particularly for prosthetic valve infective endocarditis.
Recent guidelines have suggested the use of positron emission
tomography or radiolabeled leukocyte scintigraphy in order to
improve diagnostic accuracy (Habib 2015; Iung 2019a).
Extensive narrative reviews on infective endocarditis have
been published that describe the pathophysiology, treatments,
complications, and outcomes of this clinical entity (Avelana 2018;
Baddour 2015; Burgos 2019; Hitzenbichler 2019; Khan 2017;
Kobayashi 2019; Long 2018; Şimşek-Yavuz 2020). See Appendix 1 for
types of infective endocarditis.
The incidence of infective endocarditis varies by country. Globally,
the annual incidence of infective endocarditis has been estimated
to be between 15 and 80 cases per million persons in population-
based studies performed in Western countries (Iung 2019a; Iung
2019b). People with valve prostheses (> 4 per 1000) or with a history
of infective endocarditis (> 10 per 1000) are at a higher risk (Iung
2019a). Right-sided infective endocarditis represents 5% to 10% of
infective endocarditis cases (Delahaye 2019).
There are di&erences in the epidemiology of infective endocarditis
between high- and low-income countries (Ambrosioni 2017). In
high-income countries, the proportion of cases of endocarditis
a&ecting prosthetic valves or cardiovascular implantable
electronic devices has increased (Ambrosioni 2017; Cecchi 2015).
Furthermore, there has been an increase in nosocomial cases and
infective endocarditis caused by staphylococci and enterococci
(Ambrosioni 2017; Cecchi 2015; Ursi 2019). On the other hand,
in low-income countries, rheumatic heart disease remains the
principal risk factor, and the most frequent causative agents are
streptococci (Ambrosioni 2017).
According to the results of the European Infective Endocarditis
registry, this complex clinical infectious entity remains a life-
threatening disease with a high mortality despite improvements
in diagnosis and therapy (Habib 2019). Infective endocarditis is a
serious disease with an in-hospital mortality of 20%, a five-year
mortality of 40%, and significant morbidity (Selton-Suty 2019).
One potential reason for increasing mortality is the long latency
from the onset of symptoms to reaching a definitive diagnosis
of infective endocarditis, initiating appropriate treatment and an
aging population (Cresti 2017; Iung 2019a; Mgbojikwe 2019). At-risk
groups for developing infective endocarditis include people with
valve replacements, congenital heart disease, chronic rheumatic
heart disease, cardiac implantable electronic devices, nosocomial
infection, HIV, diabetes mellitus, older age, cancer, poor oral
hygiene, dialysis for renal impairment, and intravenous drug use
(Amat-Santos 2015; Bai 2017; Beteille 2018; Burgos 2019; Egbe
2019; Elbatarny 2019; Krčméry 2019; Leahey 2019; Lin 2019; Lluri
2018; Meshaal 2018; Moriyama 2019; Muñoz-Moreno 2019; R 2018;
Sadeghi 2019; Salvador 2017; Süzük 2016; Wei 2019; Yoshioka
2018). It has recently been demonstrated that the Sequential Organ
Failure Assessment (SOFA) score could be useful for appraising the
severity and outcome of individuals with endocarditis (Asai 2019).
Common causative organisms of infective endocarditis include Oral
(or Viridans Group) streptococci (VGS) (Vinh 2016), Staphylococcus
aureus, and enterococci (Beganovic 2018; Dhotre 2018; Erdem
2019; Krčméry 2019; Kumar 2019; Ogura 2019; Salvador 2017).
In particular,VGS is found in the mouth, and it is thought that
dental procedures can lead to bacterial endocarditis (Dhotre 2018).
Current evidence shows that the most common causative agent
of infective endocarditis is S aureus (Vogkou 2016). S. aureus is
an organism associated with prosthetic valves and intravenous
drug use (Elbatarny 2019). Slipczuk and colleagues conducted
a comprehensive review of the changes in the microbiology of
infective endocarditis over the past five decades (1960s to 2000s)
(Slipczuk 2013). They noted that the proportion of cases caused by
staphylococcal and enterococcal infections increased, whereas the
numbers due to oral VGS decreased.
Overall, enterococci are the third most common causal
microorganisms of infective endocarditis, causing 5–20% of cases
(Skinner 2016).
The pathogenesis of infective endocarditis is very complex and
starts with endocardial injury (Chopra 2007; Thiene 2006). The
prototypical lesion of infective endocarditis, the vegetation, is
a mass of platelets, fibrin, microcolonies of micro-organisms,
and scant inflammatory cells (Karchmer 2009). In general, the
endothelial lining of the heart and its valves is resistant to infection;
however, very virulent micro-organisms, such as S aureus, are
able to infect normal heart valves (Melehani 2016; Werdan 2014).
Most oOen, the pathogenesis of infectious endocarditis begins with
endothelial cell damage. Congenital or acquired cardiac lesions
may induce continuous endocardial trauma via regurgitant flow
or high-pressure jets of blood through stenotic lesions (Keynan
2013). Endothelial damage triggers thrombus formation caused
by deposition of fibrin and platelets (Shannon 2010; Thurlow
2010). When transient bacteraemia occurs, bacteria can then
reach these injury sites and colonise them (Keynan 2013; Widmer
2006). AOer colonisation, the surface is quickly covered by an
additional layer of platelets and fibrin that is suitable for further
colonisation, leading to progressive bacterial infection. Moreover,
the injury site is further covered by a layer of exopolysaccharide
that hinders the penetration of antibiotics (Daga 2011). There
is proliferation of these micro-organisms and biofilm formation.
Biofilm represents multilayered bacterial aggregate containing a
polysaccharide and proteinaceous matrix that favours the bacteria
to escape the immune system and hinders antimicrobial action
(Colomer-Winter 2018; de Jong 2019; Flemming 2010; Flemming
2016; Guerra 2017; Nasser 2019; Tran 2019). AOer colonisation, an
additional layer of platelets and fibrin cover the surface, leading
to further colonisation and progressive bacterial infection and
vegetation formation (Jung 2015). Vegetation is the prototypic
lesion of infectious endocarditis, and is a mass of platelets, fibrin,
micro-organisms, and inflammatory cells (Karchmer 2009).
The clinical features of infective endocarditis are highly variable
and depend on the micro-organisms involved as well as the
presence or absence of pre-existing heart disease (Song 2015;
Sun 2015). The clinical presentation may be acute and rapidly
progressive or subacute and chronic (Habib 2019). Fever is present
in about 90% of those a&ected and is associated with various
systemic symptoms such as loss of appetite and weight (Ba
A comparison of dierent antibiotic regimens for the treatment of infective endocarditis (Review)
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2017; El Rafei 2016). A heart murmur is present in about 85% of
people (Damasco 2019). The clinical features include neurological
symptoms and signs (Champey 2016; Nascimento 2019; Sotero
2019). Infective endocarditis is a risk factor for stroke (Cantier 2019;
Cao 2018; Shao 2019).
A recent meta-analysis found a better prognosis of infective
endocarditis in people with mechanical valves compared with
those with biological valves (Tao 2017); the clinical features of
infective endocarditis are summarised in Appendix 2.
Infective endocarditis is generally thought to be lethal if
leO untreated, although evidence of infection may be found
incidentally during valve surgery (Grisoli 2014). Successful
treatment of infective endocarditis relies on microbial eradication
by antimicrobial drugs; surgical intervention is sometimes needed
to remove infected material and drain abscesses and reconstruct
or replace damaged valves (Giacobbe 2019). However, the risk
of mortality aOer surgical treatment of infective endocarditis is
high due to several risk of factors, i.e., multivalvular a&ection,
female sex, previous cardiac surgery, congestive heart failure,
age, no blood cultures before referral, body mass index, renal
failure, ischemic heart disease, inadequate response to medical
treatment, prolonged aortic cross-clamp and cardiopulmonary
bypass time, embolization, peri-annular extension of infection,
Staphylococcus aureus infection, paravalvular abscess, vegetations
> 2.2 cm, pericardial e&usion, and septic or cardiogenic shock
(Jakuska 2019; Nagy 2018; Singer 2017; Varela 2019).
Description of the intervention
Clinical pharmacology and microbiological spectrum
Many antimicrobial drugs have been used alone or in combination
to treat infective endocarditis (Vinh 2016). These include beta-
lactams, aminoglycosides, glycopeptides, oxazolidinones, complex
macrocyclics, and quinolones (Cunha 2015; Drees 2006; Frank 2009;
Pabilona 2015). See Appendix 3 for more details.
Antibiotic adverse reactions
The major antibiotic adverse reactions associated with the main
antimicrobial drugs for treating infective endocarditis are well
described (Granowitz 2008). See Appendix 3 for more details.
Guideline recommendations for the treatment of infective
endocarditis
According to international guidelines, treatment of infective
endocarditis should use bactericidal antibiotics, administered
parenterally, at high dosages, typically for prolonged periods (four
to six weeks) (Baddour 2015; Habib 2019). Where possible, the
choice of antibiotic should be directed at the microbial agent
isolated from blood cultures, according to the sensitivity pattern
identified (Baddour 2015; Habib 2019). In general, the guidelines
also recommend the combination of an aminoglycoside with
a cell wall inhibitor (i.e. beta-lactams and glycopeptides) for
synergistic bactericidal activity, to shorten the duration of therapy
(e.g. oral streptococci) and to eradicate resistant organisms (e.g.
Enterococcus spp.) (Baddour 2015; Habib 2019).
The recommended doses and schedules of the main antibiotics for
treating infective endocarditis are shown in Appendix 3.
How the intervention might work
Appropriate antibiotic treatment is important to control local and
systemic infection, eradicate the organisms from the vegetations,
and reduce the risk of complications such as septic embolisation
(Baddour 2015).
Why it is important to do this review
The recommended treatment of infective endocarditis still varies
between guidelines (Murphy 2019; Saraste 2019). This first update
of a review previously published in 2016, Marti-Carvajal 2016, has
been performed to identify and review the latest evidence. This
is of great importance, as is has been reported that around the
world experts in infective endocarditis management do not follow
international consensus guidelines on the particular point of the
use of antibiotics (Tissot-Dupont 2017).
In summary, the principal research question of this updated
Cochrane Review was: 'Which antibiotic regimens are superior in
treating people with infective endocarditis?'. A secondary question
was: 'What are the clinical benefits and harms of those regimens?'.
O B J E C T I V E S
To assess the existing evidence about the clinical benefits and
harms of di&erent antibiotics regimens used to treat people with
infective endocarditis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included parallel randomised controlled trials (RCTs),
randomised at the level of the participant. It is not possible to
conduct a trial with another design for infective endocarditis. We
included studies reported as full text, those published as abstract
only, and unpublished data.
Types of participants
Adults (aged 18 years or older) with a definitive diagnosis
of infective endocarditis, according to modified Duke's criteria
(Durack 1994; Li 2000). This requires the presence of two major
criteria, or one major and three minor criteria, or five minor criteria,
or micro-organisms demonstrated by culture or histology of a
vegetation, embolised vegetation, or in an intracardiac abscess,
or histological evidence of active endocarditis (vegetation or
intracardiac abscess) (Tam 2016).
Major criteria
• Positive blood cultures for infective endocarditis
In the absence of a primary focus, positive cultures from two
separate blood cultures of one of the following typical organisms.
• Viridans group streptococci
• Streptococcus bovis
• HACEK group (Haemophilus species, Actinobacillus
actinomycetes comitants, Cardiobacterium hominis, Eikenella
species, Kingella kingae)
• Community-acquired S. aureus or enterococci
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OR
• Persistently positive blood cultures of a micro-organism
consistent with infective endocarditis
OR
• Single blood culture for Coxiella burnetii or antiphase I
immunoglobulin (Ig)G antibody titre greater than 1:800
• Evidence of endocardial involvement
• New valvular regurgitation
OR
• Positive echocardiogram (oscillating intracardiac mass in the
absence of an alternative anatomic explanation OR abscess
OR new partial dehiscence of prosthetic valve)
Minor criteria
• Predisposing heart condition OR intravenous drug use
• Fever (at least 38.0 °C)
• Vascular phenomena (arterial emboli, septic pulmonary
infarcts, mycotic aneurysm, intracranial haemorrhage,
conjunctival haemorrhage, Janeway lesions)
• Immunological phenomena (glomerulonephritis, Osler's nodes,
Roth spots, positive rheumatoid factor)
• Microbiological evidence of positive blood culture not meeting
major criterion but excluding single positive culture for
coagulase-negative staphylococci and organisms that do not
cause endocarditis OR serological evidence of active infection
with organism consistent with infective endocarditis.
We excluded people with possible infective endocarditis (e.g. with
one major and one minor criteria, or three minor criteria).
We excluded pregnant women with endocarditis because drugs
such as tetracyclines and chloramphenicol have well-described
fetal or neonatal adverse e&ects and should be avoided. In general,
however, human studies on the safety of many antimicrobial agents
in pregnancy and lactation are limited, and antimicrobial agents
should be prescribed with caution (Leekha 2011).
We included trials with mixed populations, that is trials where only
a subset of participants met our eligibility criteria. We obtained
outcome data for the subset of interest.
Types of interventions
Antibiotic therapy (monotherapy or combinations) compared with
any other active antibiotic treatment at any dose, administration
route, or duration. We excluded surgical interventions.
We compared di&erent antibiotic classes, used as single agents
or in combination, as well as di&erent durations of treatment. We
compared antibiotics when used empirically and also when used
against sensitive bacteria. We made the following comparisons.
• The standard antibiotics suggested by guidelines according to
the sensitivity of isolated bacteria (Habib 2019).
• Streptococcus
* Penicillin (amoxicillin or ampicillin or penicillin G) or
ceOriaxone for four weeks versus penicillin (amoxicillin or
ampicillin or penicillin G) or ceOriaxone with gentamicin
or netilmicin for two weeks, or vancomycin for four weeks
with gentamicin for two weeks.
• Enterococcus
* Ampicillin or amoxicillin with gentamicin for four or six
weeks versus vancomycin with gentamicin for six weeks.
• S aureus
* Cloxacillin or oxacillin for four or six weeks with
gentamicin for three to five days versus vancomycin for
four to six weeks with gentamicin for three to five days, or
cloxacillin or oxacillin for four or six weeks with gentamicin
for three to five days and rifampicin for six weeks or
vancomycin for four to six weeks with gentamicin three to
five days and rifampicin for six weeks.
* Levofloxacin plus cloxacillin or dicloxacillin versus
cloxacillin or dicloxacillin for 14 days.
• Standard antibiotics suggested by guidelines versus no standard
regimen or new drugs, according to sensitivities of isolated
bacteria.
• Di&erent empirical antibiotics for treating native or prosthetic
valve infective endocarditis.
Types of outcome measures
Primary outcomes
• All-cause mortality (without the time points).
• Cure, defined as: disappearance of fever, sterilisation of blood
cultures, and normalisation of inflammatory markers during
treatment and in the subsequent four weeks (Baddour 2015;
Hoen 2006).
• Adverse events including treatment-related adverse events
(TRAE) (Ioannidis 2004), at any time of the treatment. We
defined TRAE as: "a response to a drug which is noxious
and uninitiated and which occurs at doses normally used in
man for prophylaxis, diagnosis, or therapy of disease, or for
the modification of physiologic functions" (Nebeker 2004). We
extracted the number of participants with at least one TRAE out
of the total randomised in each study arm.
Secondary outcomes
• Incidence of septic embolism (number of participants out of the
total randomised), at longest available follow-up.
• Incidence of congestive heart failure (number of participants
out of the total randomised) at the first 15 days of treatment
(arbitrary election).
• Quality of life (as measured by a validated scale), at longest
available follow-up.
• Need for cardiac surgical interventions (valve reconstruction
or valve replacement) (number of participants who underwent
surgery of the total randomised), at longest available follow-up
(Elmistekawy 2016).
* Indication for cardiac surgical intervention:
□ haemodynamic compromise;
□ persistent or uncontrolled infection (or both) despite
aggressive medical therapy;
□ embolisation.
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• Uncontrolled infection (persisting infection, perivalvular
extension), at longest available follow-up.
• Relapse of endocarditis (new onset of fever, chills, or other
evidence of systemic toxicity caused by the same species within
six months of the initial episode), at longest available follow-up.
Reporting one or more of the outcomes listed here in the trial
was not an inclusion criterion for this review. However, when a
published report did not appear to report one of our outcomes, we
neither accessed the trial protocol nor contacted the trial authors to
ascertain whether the outcomes were measured but not reported.
Search methods for identification of studies
Electronic searches
We searched the following electronic databases on 6 January 2020:
• the Cochrane Central Register of Controlled Trials (CENTRAL)
(Issue 1 of 12, 2020) (the Cochrane Library);
• Epub Ahead of Print, In-Process & Other Non-Indexed Citations,
MEDLINE Daily and MEDLINE (Ovid, 1946 to 3 January 2020);
• Embase Classic and Embase (Ovid, 1947 to 3 January 2020);
• LILACS via Virtual Health Library (Latin American and Caribbean
Health Science Information database) (BIREME, 1982 to 6
January 2020);
• CINAHL Plus with Full Text (Cumulative Index to Nursing and
Allied Health Literature) (EBSCO, 1937 to 6 January 2020);
• Conference Proceedings Citation Index – Science (CPCI-S) on the
Web of Science (Clarivate Analytics, 1990 to 6 January 2020).
The search strategies are shown in Appendix 4. The Cochrane
sensitivity-precision maximising RCT filter was applied to MEDLINE,
and for Embase, terms as recommended in the Cochrane Handbook
for Systematic Reviews of Interventions were applied (Lefebvre
2011). For the other databases, except CENTRAL, an adaptation of
the Cochrane RCT filter was applied.
We imposed no date or language of publication restrictions.
Searching other resources
We searched the World Health Organization (WHO)
International Clinical Trials Registry Platform (apps.who.int/
trialsearch/), US National Institutes of Health Ongoing Trials
Register ClinicalTrials.gov (clinicaltrials.gov), and the ISRCTN
(www.isrctn.com/) for ongoing and unpublished trials on 17 March
2020.
We checked the reference lists of all included trials identified by the
above methods.
Data collection and analysis
We summarised data using standard Cochrane methods (Higgins
2011). We constructed 'Summary of findings' tables and used the
GRADE approach to assess the quality of included studies.
Selection of studies
Two review authors (AMC, CMA) independently screened the titles
and abstracts of all studies identified as a result of the search for
potential relevance, coding them as 'retrieve' (eligible or potentially
eligible/unclear) or 'do not retrieve'. In case of disagreement, two
review authors (AGG, MD) were asked to arbitrate. We retrieved
the full-text study reports/publications, and three review authors
(AMC, LOC) independently screened the full texts and identified
studies for inclusion, and identified and recorded reasons for
exclusion of ineligible studies. Any disagreements were resolved
through discussion or by consulting a third review author (MD)
if necessary. We identified and excluded duplicates and collated
multiple reports of the same study so that each study, rather than
each report, was the unit of interest in the review. We recorded
the selection process in su&icient detail to complete a PRISMA flow
diagram and 'Characteristics of excluded studies' table (Liberati
2009).
Data extraction and management
Two review authors (AMC, AGG) independently extracted data from
the included trials. We extracted the following data overall.
• Participants: demographics (mean age, age range, gender,
country, N randomised, N lost to follow-up, N analysed, severity
of condition, diagnostic criteria, inclusion criteria, exclusion
criteria).
• Methodological characteristics of the trial (allocation
concealment, blinding, etc.). These data were extracted and
included in the 'Risk of bias' assessment. We also extracted
information on the design, total duration of the study, number
of study centres and location, study setting, and study date for
the Methods section of the Characteristics of included studies
tables.
• Interventions: characteristics of infective endocarditis
(anatomic site, type of a&ected valve), type of antibiotic
and characteristics of its administration (names, alone or
in combination). We also extracted data about concomitant
medications and excluded medications, if this information was
available.
• Outcomes: clinical outcomes, either primary or secondary, such
as were reported into the included trial, including time points
reported.
• Notes: funding for trial, and notable conflicts of interest of trial
authors.
We discussed any discrepancies. One review author (AMC)
transferred data into Review Manager 5 (Review Manager 2014).
Two review authors (AMC, MD, CMA) double-checked that data
were entered correctly by comparing the data presented in
the systematic review with the study reports. Three review
authors (LOC, AGG, CMA) spot-checked the study characteristics for
accuracy against the trial report.
Assessment of risk of bias in included studies
Three review authors (AMC, LOC, AGG) independently assessed the
risk of bias in pairs of each trial using a simple form, following
the domain-based evaluation as described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Any disagreements were resolved by discussion.
We assessed the following domains as low, high, or unclear risk of
bias:
• generation of allocation sequence;
• allocation concealment;
• blinding (of participants, personnel, and outcome assessors);
• incomplete outcome data;
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• selective reporting;
• other sources of bias.
See Appendix 5 for criteria used for assessing risk of bias.
Measures of treatment eect
We did not conduct a meta-analysis as studies used di&erent
antibiotic regimens. We will apply the following procedures in the
future if possible.
For dichotomous data (incidence of septic embolism and incidence
of congestive heart failure), we will present results as summary
risk ratios (RRs) with 95% confidence intervals (CIs). For continuous
data (quality of life), we will present results as mean di&erence
(MD) if the studies report continuous data on the same scale and
standardised mean di&erences (SMDs) with 95% CIs if studies report
di&erent scales.
We presented results as RRs with 95% CIs for all-cause mortality
during hospital stay and all-cause mortality at one year, cure,
adverse events including TRAEs, need for cardiac surgical
interventions, uncontrolled infection, and relapse of endocarditis.
Unit of analysis issues
The unit of analysis was the participants with infective endocarditis.
In the case of trials with more than two arms, we compared families
of antibiotics, that is glycopeptides plus aminoglycoside versus
beta-lactam plus aminoglycoside.
Dealing with missing data
We did not perform sensitivity analysis for per-protocol, worse-
case, and best-case scenarios as no meta-analysis was performed
(Hollis 1999). In the case of missing data on participants or missing
statistics (such as standard deviations) in future updates, we will
contact the trial authors.
Assessment of heterogeneity
We were unable to pool findings to perform meta-analysis as
the studies used di&erent antibiotic regimens. For future updates,
we will use the I2 statistic to measure statistical heterogeneity
between the trials in each analysis if possible. The I2 statistic
describes the percentage of total variation across trials that is due
to heterogeneity rather than to sampling error (Higgins 2003). In
future updates, we will visually inspect the forest plots. There is
substantial uncertainty in the value of I2 when there is only a small
number of studies, in which case we will also consider the P value
from the Chi2 test.
Assessment of reporting biases
If in future updates we include 10 or more trials, we will attempt to
assess whether the review is subject to publication bias by using a
funnel plot. If we detect asymmetry, we will explore other causes
(e.g. selective outcome reporting, poor methodological quality in
smaller studies, true heterogeneity) (Sterne 2011).
Data synthesis
We did not conduct a meta-analysis. For future updates, if
the eligible trials are su&iciently comparable in their clinical
characteristics, we will summarise their findings using both fixed-
e&ect and random-e&ects models. In the presence of statistical
heterogeneity and the absence of small-study e&ects, we expect
the 95% CI from the random-e&ects model to include the 95% CI
from the fixed-e&ect model. In such a case, we will report only the
data using the random-e&ects model as it appropriately conveys
heterogeneity. If substantial di&erences are observed between both
models, we will investigate this further.
Subgroup analysis and investigation of heterogeneity
We anticipate clinical heterogeneity for the following participants
and intervention characteristics, therefore we will carry out the
following subgroup analyses in future updates if possible.
• People at highest risk for a complicated or lethal course
of infective endocarditis (people with valvular prosthesis
(mechanical or biological), people who have previously had
endocarditis, people with certain congenital heart defects,
and heart-transplant recipients who have developed a cardiac
valvulopathy).
• People aged over 60 years.
• People with culture-negative endocarditis versus people with
infective endocarditis with positive blood cultures.
• Right-sided versus leO-sided infective endocarditis.
• Type of infective organism.
• People with native-valve endocarditis versus people with
prosthetic-valve endocarditis.
• People with community-acquired endocarditis versus
healthcare-associated endocarditis or endocarditis that
developed aOer a surgical procedure.
• Monotherapy versus combination therapy.
We plan to restrict subgroup analysis to primary outcomes only
(Higgins 2011).
Sensitivity analysis
For future updates, if su&icient trials are identified and pooled, we
will conduct a sensitivity analysis comparing the results using all
the included trials.
• Including only RCTs with a low risk of bias (Higgins 2011). It is
unlikely that we will find many trials at low risk of bias in all 'Risk
of bias' domains, therefore we will choose three core domains
only: generation of allocation sequence, incomplete outcome
data, and selective reporting bias.
• Sensitivity analyses taking concealment of allocation and
attrition into consideration.
'Summary of findings' tables
We used the principles of the GRADE system to assess the quality
of the body of evidence associated with all main outcomes (all-
cause mortality during hospital stay and all-cause mortality at one
year, cure, adverse events, TRAE, incidence of congestive heart
failure, incidence of septic embolism, need for cardiac surgical
intervention) (Guyatt 2008), and constructed 'Summary of findings'
tables using GRADEpro GDT soOware (GRADEpro 2008). The GRADE
approach appraises the quality of a body of evidence based on the
extent to which one can be confident that an estimate of e&ect
or association reflects the item being assessed. Evaluation of the
quality of a body of evidence considers within-study risk of bias,
directness of the evidence, heterogeneity in the data, precision of
e&ect estimates, and risk of publication bias (Balshem 2011; Guyatt
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2011a; Guyatt 2011b; Guyatt 2011c; Guyatt 2011d; Guyatt 2011e;
Guyatt 2011f; Guyatt 2011g; Guyatt 2011h).
One review author (AMC) constructed 'Summary of findings' tables,
and another review author (AGG) assessed the quality of evidence:
Summary of findings 1; Summary of findings 2; Summary of
findings 3; Summary of findings 4; Summary of findings 5; Summary
of findings 6.
R E S U L T S
Description of studies
Results of the search
Searching from the previous review to January 2020 (latest search),
we identified 415 records in the database searches and 14 records
from clinical trials registers. There were 351 unique references
aOer removal of duplicates. We excluded a further 347 references
aOer title and abstract screening. We obtained the full texts of the
remaining four references for more detailed examination. These
four references were for two new RCTs (Pericas 2018; POET 2019).
This updated review includes a total of six RCTs, published between
1998 and 2019, involving 1143 participants (FINLEVO Trial 2006;
Fortún 2001; Fowler 2006; Pericas 2018; POET 2019; Sexton 1998).
See Figure 1 for details of study selection.
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Figure 1.   Study flow diagram.
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The length of follow-up ranged from 28 days to six months. The
trials varied in size, characteristics of participant populations,
duration, drug dosage, and experimental design. For study details
see Characteristics of included studies.
Included studies
For study details see Characteristics of included studies.
Interventions
The following comparisons were evaluated in the included trials.
A quinolone plus standard treatment versus standard treatment
A quinolone, levofloxacin, at a dose of 500 mg once daily for
participants weighing less than 60 kg and 500 mg twice daily for
participants weighing over 60 kg, administered both intravenously
and orally, was compared with standard treatment. Standard
treatment comprised cloxacillin or dicloxacillin 2 g every four hours,
intravenously. Participants with contraindications to penicillin
received cefuroxime (1.5 g every six hours, clindamycin 600 mg
every six or eight hours, or vancomycin 1 g twice daily). When
oral treatment was indicated, cloxacillin 500 mg every six hours,
cephalexin or cefadroxil 500 mg every six hours, or clindamycin
300 mg every six hours was used. Doses were adjusted according
renal function. Furthermore, an aminoglycoside, tobramycin or
netilmicin at 1 mg/kg body weight every eight hours, and rifampicin
450 mg once daily for participants weighing under 50 kg and
600 mg once daily for participants weighing over 50 kg, oral or
intravenously was used (FINLEVO Trial 2006).
A glycopeptide plus an aminoglycoside versus a beta-lactam plus an
aminoglycoside
Vancomycin 500 mg intravenous every six hours with gentamicin
1.5 mg/kg every eight hours for two weeks, or teicoplanin 12 mg/
kg every 24 hours, with a loading dose of 24 mg/kg given on the
first day with gentamicin 1.5 mg/kg every eight hours for two weeks
was compared with cloxacillin 2 g intravenously every four hours
with gentamicin 1.5 mg/kg every eight hours for two weeks (Fortún
2001).
A lipopeptide antibiotic (daptomycin) versus either antistaphylococcal
penicillins or a glycopeptide antibiotic plus an aminoglycoside
Daptomycin 6 mg/kg intravenously once daily was compared with
standard therapy with either vancomycin 1 g every 12 hours or
nafcillin, oxacillin, or flucloxacillin 2 g every four hours (depending
on the susceptibility of the causative strain to methicillin) plus
gentamicin 1 mg/kg intravenously every eight hours for the
first four days. The duration of therapy was determined by the
investigators, but the median duration of therapy was 14 days for
daptomycin and 15 days for standard therapy (Fowler 2006).
A beta-lactam plus an aminoglycoside versus a beta-lactam alone
CeOriaxone 2 g intravenously once daily for two weeks was
compared with ceOriaxone 2 g intravenously once daily with
gentamicin 3 mg/kg (of ideal body weight) once daily for two weeks
(Sexton 1998).
Two studies determined gentamicin levels (Fortún 2001; Sexton
1998), and one study determined vancomycin and teicoplanin
levels (Fortún 2001). One study did not report if the antibiotic levels
were determined (Fowler 2006).
Fosfomycin plus imipenem versus vancomycin
Fosfomycin 2 g intravenously six hourly plus imipenem 1 g
intravenously six hourly, adjusted for renal function, was compared
with vancomycin 30 to 45 mg/kg daily intravenously divided into
two to three doses, ensuring trough levels ≥ 15 mg/L (Pericas
2018). If the participant developed either treatment failure or renal
failure with vancomycin, he/she was switched to the fosfomycin/
imipenem group.
Partial oral treatment versus conventional intravenous treatment
AOer an initial period of conventional intravenous treatment,
a switch to oral medication was compared to continuing with
conventional intravenous treatment. This treatment strategy was
based on the guidelines of the European Society of Cardiology
(Habib 2015), with modifications endorsed by the Danish Society of
Cardiology (Moser 2017). The composition, doses, and duration of
di&erent oral regimens are described in Appendix 6 and Appendix
7. No details were provided regarding the conventional intravenous
therapy regimens (POET 2019).
Participants
The included trials involved a total of 1143 randomised participants
(median 156.5; range 34 to 381).
Five trials reported the age of the participants, which ranged
between 18 and 92 years (FINLEVO Trial 2006; Fortún 2001;
Pericas 2018; POET 2019; Sexton 1998). Male participants were
predominant in five trials: 60% in FINLEVO Trial 2006, 97.5% in
Fortún 2001, 76% in POET 2019, and 80% in Sexton 1998. One trial
did not report the gender of the participants (Fowler 2006). One
trial showed inconsistency regarding the frequency of this variable
between comparison groups (Pericas 2018).
Only two trials included people diagnosed as having definitive
and probable endocarditis (FINLEVO Trial 2006; Fowler 2006). Four
trials only included people with infective endocarditis (Fortún 2001;
Pericas 2018; POET 2019; Sexton 1998). One trial only included
right-sided endocarditis (Fortún 2001); two trials included leO-
sided endocarditis (POET 2019; Sexton 1998); and three trials
reported data of participants irrespective of the side of the valve
a&ected by endocarditis (FINLEVO Trial 2006; Fowler 2006; Pericas
2018).
The included trials were conducted to assess the e&ect of the
intervention on di&erent micro-organisms: methicillin-susceptible
S aureus (Fortún 2001), S aureus (FINLEVO Trial 2006; Fowler 2006),
and ceOriaxone-susceptible viridans group streptococci or S bovis
endocarditis (Sexton 1998). Two trials only included endocarditis
a&ecting native valves (Fortún 2001; Sexton 1998). Two trials
involved participants with either native or prosthetic valves (Fowler
2006; POET 2019). Two trials reported data from participants with
S aureus bacteraemia, a subset of whom had endocarditis: 70
participants in FINLEVO Trial 2006 and 52 participants in Fowler
2006.
Methods
The included trials were conducted between 1998 and 2019 and
used a parallel design (FINLEVO Trial 2006; Fortún 2001; Fowler
2006; Pericas 2018; POET 2019; Sexton 1998). Five trials had two
arms (FINLEVO Trial 2006; Fowler 2006; Pericas 2018; POET 2019;
Sexton 1998), and one trial had three arms (Fortún 2001). There
A comparison of dierent antibiotic regimens for the treatment of infective endocarditis (Review)









Cochrane Database of Systematic Reviews
were five multicentre trials (FINLEVO Trial 2006; Fowler 2006;
Pericas 2018; POET 2019; Sexton 1998). One trial was conducted
in Finland (FINLEVO Trial 2006), one trial in Denmark (POET 2019),
two trials in Spain (Fortún 2001; Pericas 2018), and two trials in the
USA (Fowler 2006; Sexton 1998). The follow-up of the trials ranged
between 28 days, (FINLEVO Trial 2006) and six months (POET 2019).
Four trials reported a priori sample size estimation (FINLEVO Trial
2006; Fowler 2006; Pericas 2018; POET 2019). The median number
of outcomes reported by any trial was six (minimum four, maximum
seven). One trial included a composite outcome involving four
components (POET 2019). Two trials without a priori sample size
estimation assessed six outcomes each (Fortún 2001; Sexton 1998).
Excluded studies
We excluded 10 RCTs that did not meet Duke's criteria for
diagnosis of infective endocarditis (Abrams 1979; Fortún 1995;
Gilbert 1991; Greenman 1984; Heldman 1996; Korzeniowski 1982;
Levine 1991; Markowitz 1992; Ribera 1996; Stamboulian 1991). See
Characteristics of excluded studies.
Ongoing trials
We identified 14 ongoing trials (CTRI/2008/091/000060;
EUCTR 2016-003059-31; EUCTR 2017-001699-43; EudraCT
2008-008683-28; JPRN-UMIN 000032006; NCT00638157;
NCT00695903; NCT02208063; NCT02701595; NCT02701608;
NCT03138733; NCT03148756; NCT04222257; RBR-3p8g7n 2016).
See Characteristics of ongoing studies.
Risk of bias in included studies
The risk of bias in the included trials is summarised in Figure 2
and Figure 3, and detailed in the Characteristics of included studies
table.
 
Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias): All outcomes
Blinding of outcome assessment (detection bias): Cure
Blinding of outcome assessment (detection bias): All-cause mortality
Blinding of outcome assessment (detection bias): Adverse events
Blinding of outcome assessment (detection bias): Incidence of septic embolism
Blinding of outcome assessment (detection bias): Incidence of congestive heart failure
Blinding of outcome assessment (detection bias): Quality of life
Blinding of outcome assessment (detection bias): Need for cardiac surgical interventions
Blinding of outcome assessment (detection bias): Indication of cardiac surgery
Blinding of outcome assessment (detection bias): Uncontrolled infection
Blinding of outcome assessment (detection bias): Relapse
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
Other bias
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A comparison of dierent antibiotic regimens for the treatment of infective endocarditis (Review)









Cochrane Database of Systematic Reviews






















































































































































































































































































































































































































































































FINLEVO Trial 2006 ? ? - ? ? ? ? ? ? ? ? ? ? ? ? -
Fortún 2001 ? ? - + + + + + + + + + + + ? -
Fowler 2006 + + - + + + + + + + + + + + - -
Pericas 2018 ? ? - ? ? ? ? ? ? ? ? ? ? + + -
POET 2019 + + - ? ? ? ? ? ? ? ? ? ? + + +
Sexton 1998 ? ? - + + + + + + + + + + - - -
 
We considered all trials as at high risk of bias.
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Allocation
Random sequence generation
The risk of bias arising from the method of generation of the
allocation sequence was low in two trials (Fowler 2006; POET 2019).
Four trials had an unclear risk of bias (FINLEVO Trial 2006; Fortún
2001; Pericas 2018; Sexton 1998).
Allocation concealment
The risk of bias arising from the method of generation of the
allocation sequence was low in two trials (Fowler 2006; POET 2019).
Four trials had an unclear risk of bias (FINLEVO Trial 2006; Fortún
2001; Pericas 2018; Sexton 1998).
Blinding
The risk of bias due to lack of blinding of participants and personnel
was high in all trials (FINLEVO Trial 2006; Fortún 2001; Fowler 2006;
Pericas 2018; POET 2019; Sexton 1998).
Blinding of outcome assessment (detection bias)
For all-cause mortality, the risk of bias was low risk in three trials,
FINLEVO Trial 2006; Fortún 2001; POET 2019, and unclear in three
trials (Fowler 2006; Pericas 2018; Sexton 1998).
For cure, we rated Fortún 2001, Fowler 2006, and Sexton 1998 as at
low risk of bias for blinding of outcome assessment. We rated one
trial as having an unclear risk of bias (Pericas 2018). POET 2019 did
not assess this outcome.
For adverse events, three trials were at low risk of bias (Fortún 2001;
POET 2019; Sexton 1998), and three trials were at unclear risk of bias
for blinding of outcome assessment (FINLEVO Trial 2006; Fowler
2006; Pericas 2018).
For incidence of septic embolism, one trial was at low risk of bias
(POET 2019), and five trials were at unclear risk of bias (FINLEVO
Trial 2006; Fortún 2001; Fowler 2006; Pericas 2018; Sexton 1998).
For incidence of heart failure, one trial was at low risk of bias (POET
2019), and five trials were at unclear risk of bias (FINLEVO Trial 2006;
Fortún 2001; Fowler 2006; Pericas 2018; Sexton 1998).
No trials assessed quality of life, thus we rated all trials as at unclear
risk of bias for this domain (FINLEVO Trial 2006; Fortún 2001; Fowler
2006; Pericas 2018; POET 2019; Sexton 1998).
For the need for cardiac valve reconstruction or replacement, we
assessed two trials as at low risk of bias (POET 2019; Sexton 1998),
and four trials as at unclear risk of bias (FINLEVO Trial 2006; Fortún
2001; Fowler 2006; Pericas 2018).
For indication of cardiac surgery due to embolisation,
haemodynamic compromise, or persistent infection, two trials
were at low risk of bias (POET 2019; Sexton 1998), and four trials
were at unclear risk of bias (FINLEVO Trial 2006; Fortún 2001; Fowler
2006; Pericas 2018).
For uncontrolled infection, two trials had a low risk of bias (Fowler
2006; Sexton 1998), and four trials had an unclear risk of bias
(FINLEVO Trial 2006; Fortún 2001; Pericas 2018; POET 2019).
For relapse, two trials had a low risk of bias (Fortún 2001; POET
2019), and four trials had an unclear risk of bias (FINLEVO Trial 2006;
Fortún 2001; Pericas 2018; Sexton 1998).
Incomplete outcome data
Risk of attrition bias was low in four trials (Fortún 2001; Fowler
2006; Pericas 2018; POET 2019), high in one trial (Sexton 1998), and
unclear in one trial (FINLEVO Trial 2006).
Selective reporting
Risk of selective outcome reporting bias was low in two trials
(Pericas 2018; POET 2019), high in two trials (Fowler 2006; Sexton
1998), and unclear in two trials (FINLEVO Trial 2006; Fortún 2001).
Other potential sources of bias
One trial had a low risk for other potential trial (POET 2019). Risk
of other bias was high in five trials due to bias in the presentation
of data, and design bias (FINLEVO Trial 2006; Fortún 2001; Fowler
2006; Pericas 2018; Sexton 1998).
Eects of interventions
See: Summary of findings 1 Levofloxacin compared with standard
treatment for Staphylococcus aureus endocarditis; Summary
of findings 2 Lipopeptide antibiotic (daptomycin) versus
aminoglycoside (low-dose gentamicin) plus antistaphylococcal
penicillin (nafcillin, oxacillin, or flucloxacillin) or glycopeptide
antibiotic (vancomycin) for Staphylococcus aureus endocarditis;
Summary of findings 3 Glycopeptide (vancomycin or teicoplanin)
plus aminoglycoside (gentamicin) compared with beta-lactam
(cloxacillin) plus aminoglycoside (gentamicin) for Staphylococcus
aureus endocarditis in drug abusers; Summary of findings 4 Beta-
lactam (ceOriaxone) plus aminoglycoside (gentamicin) versus beta-
lactam (ceOriaxone) for infective endocarditis due to penicillin-
susceptible streptococci; Summary of findings 5 Fosfomycin plus
imipenem compared with vancomycin for infective endocarditis
due to methicillin-resistant Staphylococcus aureus; Summary of
findings 6 Partial oral treatment compared with conventional
intravenous treatment of endocarditis on the leO side of the
heart (on native or prosthetic valves) and bacteraemia for
Streptococcus, Enterococcus faecalis, Staphylococcus aureus, or
coagulase-negative staphylococci
Results were based on 632 participants from 1143 randomised
participants. This is due to the fact that three trials were conducted
in participants with S aureus bacteraemia (FINLEVO Trial 2006;
Fowler 2006; Pericas 2018), which included a subset of participants
with infective endocarditis, but treated a broader range of
participants; we have only included the data from the participants
with endocarditis. See Summary of findings 1; Summary of findings
2; Summary of findings 3; Summary of findings 4; Summary of
findings 5; Summary of findings 6.
Primary outcomes
All-cause mortality
Quinolones (levofloxacin) plus standard treatment
(antistaphylococcal penicillin (cloxacillin or dicloxacillin),
aminoglycoside (tobramycin or netilmicin), and rifampicin) versus
standard treatment
One trial showed inconclusive evidence regarding all-cause
mortality at 28 days and 3 months (8/31 (26%) with levofloxacin
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plus standard treatment versus 9/39 (23%) with standard treatment
alone; risk ratio (RR) 1.12, 95% confidence interval (CI) 0.49 to 2.56;
very low-quality evidence) (FINLEVO Trial 2006).
Glycopeptides (vancomycin or teicoplanin) plus an aminoglycoside
(gentamicin) versus a beta-lactam (cloxacillin) plus an aminoglycoside
(gentamicin)
One trial described no deaths at least 12 weeks aOer completion of
therapy (Fortún 2001).
Fosfomycin plus imipenem versus vancomycin
One trial showed inconclusive evidence in terms of all-cause
mortality at six months (3/4 (75%) with fosfomycin plus imipenem
versus 0/4 (0%) with vancomycin; RR 7.00, 95% CI 0.47 to 103.27;
very low-quality evidence) (Pericas 2018).
Partial oral treatment versus conventional intravenous treatment
One trial showed inconclusive evidence regarding all-cause
mortality at six months (7/201 (3.48%) with partial oral treatment
versus 13/199 (6.53%) with conventional intravenous treatment; RR
0.53, 95% CI 0.22 to 1.31; very low-quality evidence) (POET 2019).
Cure
Lipopeptide antibiotics (daptomycin) versus aminoglycoside (low-
dose gentamicin) plus antistaphylococcal penicillins (nafcillin,
oxacillin, or flucloxacillin) or glycopeptide antibiotics (vancomycin)
One trial found no conclusive evidence between the two regimens
for cure (9/28 (32%) with daptomycin versus 9/25 (36%) with low-
dose gentamicin plus antistaphylococcal penicillin or vancomycin;
RR 0.89, 95% CI 0.42 to 1.89; very low-quality evidence) (Fowler
2006).
Glycopeptides (vancomycin or teicoplanin) plus an aminoglycoside
(gentamicin) versus a beta-lactam (cloxacillin) plus an aminoglycoside
(gentamicin)
One trial showed conclusive evidence between the regimens for
cure (13/23 (56%) with glycopeptides plus aminoglycoside versus
11/11 (100%) beta-lactam plus an aminoglycoside; RR 0.59, 95% CI
0.40 to 0.85; low-quality evidence) (Fortún 2001).
Beta-lactam (ceIriaxone) plus an aminoglycoside (gentamicin) versus
a beta-lactam alone (ceIriaxone)
One trial found inconclusive evidence between the regimens for
cure (15/34 (44%) with beta-lactam plus aminoglycoside versus
21/33 (64%) with beta-lactam alone; RR 0.69, 95% CI 0.44 to 1.10;
low-quality evidence) (Sexton 1998).
Fosfomycin plus imipenem versus vancomycin
One trial showed inconclusive evidence between the regimens for
cure (1/4 (25%) with fosfomycin plus imipenem versus 2/4 (50%)
with vancomycin; RR 0.50, 95% CI 0.07 to 3.55; very low-quality
evidence) (Pericas 2018).
Treatment-related adverse events
Glycopeptides (vancomycin or teicoplanin) plus an aminoglycoside
(gentamicin) versus a beta-lactam plus an aminoglycoside (cloxacillin
plus gentamicin)
One trial showed no conclusive evidence with regard to TRAEs
(5/23 (22%) with glycopeptides plus aminoglycoside versus 0/11
(0%) with beta-lactam plus aminoglycoside; RR 5.50, 95% CI 0.33 to
91.44; very low-quality evidence) (Fortún 2001).
A beta-lactam (ceIriaxone) plus an aminoglycoside (gentamicin)
versus a beta-lactam alone (ceIriaxone)
One trial found inconclusive results with regard to TRAEs (3/34
(8.8%) with beta-lactam plus aminoglycoside versus 5/33 (15%)
with a beta-lactam alone; RR 0.58, 95% CI 0.15 to 2.24; very low-
quality evidence) (Sexton 1998).
Fosfomycin plus imipenem versus vancomycin
One trial showed inconclusive evidence in terms of adverse events
(2/4 (50%) with fosfomycin plus imipenem versus 2/4 (50%) with
vancomycin; RR 1.00, 95% CI 0.25 to 4.00; very low-quality evidence)
(Pericas 2018).
Partial oral treatment versus conventional intravenous treatment
One trial showed inconclusive evidence regarding adverse events
(10/201 (4.97%) with fosfomycin plus imipenem versus 12/199
(6.03%) with vancomycin; RR 0.83, 95% CI 0.36 to 1.87; low-quality
evidence) (POET 2019).
Secondary outcomes
Incidence of septic embolism
Partial oral treatment versus conventional intravenous treatment
One trial showed inconclusive evidence regarding septic embolism
(3/201 (1.49%) with fosfomycin plus imipenem versus 3/199 (1.50%)
with vancomycin; RR 0.99, 95% CI 0.20 to 4.85; very low-quality
evidence) (POET 2019).
Incidence of congestive heart failure
Fosfomycin plus imipenem versus vancomycin
One trial showed inconclusive evidence in terms of congestive heart
failure (4/4 (100%) with fosfomycin plus imipenem versus 0/4 (0%)
with vancomycin; RR 9.00, 95% CI 0.64 to 126.85; very low-quality
evidence) (Pericas 2018).
Partial oral treatment versus conventional intravenous treatment
One trial showed inconclusive evidence regarding congestive heart
failure (0/201 (0%) with partial oral treatment versus 1/199 (0.5%)
with conventional intravenous treatment; RR 0.33, 95% CI 0.01 to
8.05; very low-quality evidence) (POET 2019).
Quality of life
No trials assessed quality of life.
Need for cardiac surgical intervention (valve reconstruction or
replacement) intervention
A beta-lactam (ceIriaxone) plus an aminoglycoside (gentamicin)
versus a beta-lactam (ceIriaxone) alone
One trial found inconclusive results in terms of need for a
cardiac surgical intervention (9/34 (26%) with beta-lactam plus
aminoglycoside versus 5/33 (15%) with beta-lactam alone; RR 1.75,
95% CI 0.65 to 4.67) (Sexton 1998).
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A beta-lactam (ceIriaxone) plus an aminoglycoside (gentamicin)
versus a beta-lactam alone (ceIriaxone)
One trial reported that one participant in the control group had
a pedunculated mobile vegetation at the time of surgery (Sexton
1998).
Fosfomycin plus imipenem versus vancomycin
One trial showed inconclusive evidence in terms of need for
a cardiac surgical intervention (2/4 (50%) with fosfomycin plus
imipenem versus 1/4 (25%) with vancomycin; RR 2.00, 95% CI 0.28
to 14.20; very low-quality evidence) (Pericas 2018).
Partial oral treatment versus conventional intravenous treatment
One trial showed inconclusive evidence regarding need for a
cardiac surgical intervention (6/201 (2.98%) with partial oral
treatment versus 6/199 (3.01%) with conventional intravenous
treatment; RR 0.99, 95% CI 0.32 to 3.02; very low-quality evidence)
(POET 2019).
Uncontrolled infection
A beta-lactam (ceIriaxone) plus an aminoglycoside (gentamicin)
versus a beta-lactam (ceIriaxone) alone
One trial found no conclusive results in terms of uncontrolled
infection (1/34 (2.9%) with a beta-lactam plus an aminoglycoside
versus 1/33 (3.0%) with a beta-lactam alone; RR 0.97, 95% CI 0.06 to
14.88; very low-quality evidence) (Sexton 1998).
Relapse of endocarditis
A beta-lactam (ceIriaxone) plus an aminoglycoside (gentamicin)
versus a beta-lactam alone (ceIriaxone)
One trial reported no relapses in either group (Sexton 1998).
Fosfomycin plus imipenem versus vancomycin
One trial showed inconclusive evidence in terms of relapse of
endocarditis (0/4 (0%) with fosfomycin plus imipenem versus 1/4
(25%) with vancomycin; RR 0.33, 95% CI 0.02 to 6.37; very low-
quality evidence) (Pericas 2018).
Partial oral treatment versus conventional intravenous treatment
One trial showed inconclusive evidence regarding relapse of
endocarditis (5/201 (2.48%) with partial oral treatment versus 5/199
(2.51%) with conventional intravenous treatment; RR 0.99, 95% CI
0.29 to 3.37; very low-quality evidence) (POET 2019).
D I S C U S S I O N
Summary of main results
This updated Cochrane Review aimed to assess the clinical
benefits and harms of di&erent antibiotic regimens to treat
infective endocarditis. Six small RCTs, involving 1143 randomised
participants, of which 632 were analysed, met our inclusion
criteria. The trials were conducted using modified Duke’s criteria
to diagnose infective endocarditis. We concluded that our main
finding suggesting that one antibiotic regimen is not superior to
another is uncertain. The included trials had a high risk of bias
and were underpowered, and three trials were sponsored by drug
companies.
The six included trials used di&erent treatment schedules in terms
of antibiotics used, routes of administration, and duration of
treatment:
• a fluoroquinolone (levofloxacin) versus standard treatment
comprised of an antistaphylococcal penicillin (cloxacillin or
dicloxacillin) plus an aminoglycoside (tobramycin or netilmicin)
and rifampicin (FINLEVO Trial 2006);
• a glycopeptide (vancomycin or teicoplanin) plus an
aminoglycoside (gentamicin) versus a beta-lactam (cloxacillin)
plus an aminoglycoside (gentamicin) (Fortún 2001);
• a lipopeptide antibiotic (daptomycin) versus an aminoglycoside
(low-dose gentamicin) plus antistaphylococcal penicillins
(nafcillin, oxacillin, or flucloxacillin) or glycopeptide antibiotics
(vancomycin) (Fowler 2006);
• fosfomycin plus imipenem versus vancomycin (Pericas 2018);
• partial oral treatment versus conventional intravenous
treatment (POET 2019); and
• a beta-lactam (ceOriaxone) plus an aminoglycoside (gentamicin)
versus a beta-lactam (ceOriaxone) alone (Sexton 1998).
Four trials reported the main outcome of this Cochrane Review,
all-cause in-hospital mortality and all-cause mortality at one year.
These trials found no conclusive di&erences between treatment
regimens (FINLEVO Trial 2006; Fortún 2001; Pericas 2018; POET
2019).
The included trials showed inconclusive e&ects with regard to
cure rates, TRAEs, the need for cardiac surgical intervention,
uncontrolled infection, incidence of septic emboli, congestive heart
failure, and relapse of endocarditis. No trials assessed quality of life.
Overall completeness and applicability of evidence
The data from this updated Cochrane Review suggest that there
is insu&icient evidence to conclude that there is no di&erence in
either clinical benefits or in the frequency of treatment-related
adverse events related to the antibiotics used to treat infective
endocarditis. Antistaphylococcal penicillins may be more e&ective
than glycopeptides.
The six small trials included participants with di&erent
comorbidities and micro-organisms who received di&erent
treatment schedules in terms of antibiotic used and duration of
therapy, therefore we were unable to conduct a meta-analysis.
The conclusions of this review are based on RCTs with a high risk of
bias. Due to insu&icient data, we were unable to draw conclusions
to guide practice. Recommendations for antibiotic treatment of
endocarditis in current guidelines are based on expert consensus,
due to a lack of evidence from RCTs to support them (Baddour 2015;
Habib 2019). Data from this review were insu&icient to refute or
corroborate such recommendations. These findings support what
was noted by Paterson 2013, that there is a need for RCTs to define
optimal treatment regimens for this serious infection.
This updated review identified six trials assessing many outcomes
with small sample sizes. Consequently, it is likely that at least
one type I error was made (Delorme 2016; Senn 2007). Two trials
without sample size estimation included many outcomes. These
trials therefore have a high risk of uncertainty of clinical significance
(Mascha 2018; Sormani 2017).
A comparison of dierent antibiotic regimens for the treatment of infective endocarditis (Review)









Cochrane Database of Systematic Reviews
Quality of the evidence
We conducted GRADE assessments. The quality of evidence of the
six included trials is shown in Summary of findings 1; Summary of
findings 2; Summary of findings 3; Summary of findings 4; Summary
of findings 5; Summary of findings 6. Overall, the included trials had
a high risk of bias (Figure 2; Figure 3) due to poor trial design and
reporting related to failure to conceal allocation, blinding, selective
outcome reporting of the six trials for the main outcomes assessed
(all-cause mortality during hospital stay and all-cause mortality
at one year, cure, TRAEs, incidence of septic embolism, incidence
of congestive heart failure, quality of life, and need for cardiac
surgical intervention). Furthermore, we downgraded the quality of
the evidence for serious imprecision due to small sample sizes and
low number of events.
Potential biases in the review process
The main potential bias in this review was the exclusion of 10 RCTs
of antibiotic therapy for the treatment of infective endocarditis
because they did not apply modified Duke’s criteria for diagnosis
(Durack 1994). Von Reyn's old criteria were outperformed by
Duke's (Bayer 1994; Von Reyn 1981). There is su&icient long-
standing evidence to support the superiority of Ducke's criteria
over Von Reyn's old criteria (Durack 1994; Holland 2016; Naber
2001), although Duke's criteria are not perfect (Iung 2019a;
Olaison 1996). Today, Dr von Reyn's statement remains valid:
"Infective endocarditis is a diagnosis that can only be confirmed
unequivocally by examination of the endocardium at surgery or
autopsy" (Von Reyn 1981).
In a systematic review process, there is a group of biases known as
significance-chasing biases, such as publication bias and selective
outcome reporting bias (Ioannidis 2010). Selective outcome
reporting bias operates through suppression of information on
specific outcomes and is similar to study publication bias in that
’negative’ results remain unpublished (Ioannidis 2010). Regarding
the risk of selective outcome reporting bias, this updated Cochrane
Review found two trials with a low risk (Pericas 2018; POET 2019),
two trials with a high risk (Fowler 2006; Sexton 1998), and two trials
with an unclear risk (FINLEVO Trial 2006; Fortún 2001). See Figure
2; Figure 3.
Agreements and disagreements with other studies or
reviews
This first update found no new systematic reviews to be discussed
in this section. Consequently, our results are similar to two non-
Cochrane Reviews (Falagas 2006; Yung 2007). These two reviews
di&ered in their eligibility criteria. One review only looked at the
management of right-side endocarditis in intravenous drug users
(Yung 2007), whereas the other review limited itself to looking
specifically at the role of aminoglycosides in combination with
beta-lactams to treat endocarditis (Falagas 2006). Our Cochrane
Review had no restrictions on micro-organism, clinical population,
or antimicrobial agent. Falagas 2006 included a pooled analysis, an
approach we decided to avoid due to the heterogeneity in outcome
definitions and di&erences in the composition of the antibiotic
regimens. This heterogeneity, along with a paucity of identified
trials, prevented us from performing any meta-analysis. Yung 2007
did not pool results because of clinical heterogeneity. Despite these
di&erences, the reviews reached similar results, that is that the
evidence from the included trials was insu&icient to support or
reject one antimicrobial regimen over another.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
This first update confirms the findings of the original version of
the review. Limited and very low-quality evidence suggests that
the comparative e&ects of di&erent antibiotic regimens in terms of
cure rates or other relevant clinical outcomes are uncertain. The
conclusions of this updated Cochrane Review were based on few
randomised controlled trials with a high risk of bias. Accordingly,
the current evidence does not support or reject any regimen of
antibiotic therapy for the treatment of infective endocarditis.
Implications for research
Infectious endocarditis is a rare disease caused by di&erent micro-
organisms, which vary according to the population at risk. This is an
obstacle to the conduct of randomised controlled trials, and should
therefore indicate a need for the co-operation of di&erent clinical
centres.
Randomised controlled trials are needed to assess the clinical
benefits and harms of the use of antibiotic regimens for
treating infective endocarditis. These trials should be high-quality
randomised trials, with a priori calculation of sample sizes, to
assess the clinical benefits and harms of antibiotics to treat
infective endocarditis, as noted by Paterson 2013. The trials
should be designed according to the SPIRIT (Standard Protocol
Items: Recommendations for Interventional Trials) statement
(Chan 2013), and reported according to the CONSORT statement for
improving the quality of reporting of e&icacy and harms in clinical
research (Ioannidis 2004; Moher 2010). Future trials should be
planned following the Foundation of Patient-Centered Outcomes
Research Institute recommendations (Basch 2012; Gabriel 2012;
McKinney 2012).
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Design: parallel (2 groups)
Multicentre study: yes
Country: Finland
Follow-up period: at 28 days and 3 months
Unit of randomisation: participants
Unit of analysis: participants
Duke's criteria for diagnosis of infective endocarditis: yes




• Standard treatment: 190
People with endocarditis: 70
• Levofloxacin: 31
• Standard treatment: 39
Age (mean) for overall participants
• Levofloxacin: 58 (SD 19) years
• Standard treatment: 58 (SD 17) years
Gender (male) for overall participants
• Levofloxacin: 61%
• Standard treatment: 64%
There was no information related solely to the baseline demographics of participants with endocardi-
tis.
FINLEVO Trial 2006 
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Interventions Experimental: levofloxacin (500 mg once daily for participants weighing < 60 kg and 500 mg twice daily
for participants weighing > 60 kg, both IV and orally + standard treatment
Control: standard treatment (cloxacillin or dicloxacillin (2 g every 4 hours), IV. Participants with a
contraindication to penicillin use: cefuroxime (1.5 g every 6 hours), clindamycin (600 mg every 6 to 8
hours), or vancomycin (1 g twice daily). When oral treatment was indicated, cloxacillin (500 mg every 6
hours), cephalexin or cefadroxil (500 mg every 6 hours), or clindamycin (300 mg every 6 hours). Doses
were adjusted according to renal function when required. Furthermore, aminoglycosides (tobramycin
or netilmicin at 1 mg/kg/body weight 3 times daily) and rifampicin (450 mg once daily for participants
weighing < 50 kg and 600 mg once daily for participants weighing > 50 kg, oral or IV) were used.
Treatment duration: 14 days
Outcomes Primary
• Case fatality rate at 28 days and 3 months
Secondary
• Number of complications (e.g. deep infections) observed after the first week
• Decrease in serum C-reactive protein concentration
• Length of antibiotic treatment
• Need for surgical intervention
• Time to apyrexia (days until axillary temperature < 37.5 °C)
Notes Conduction date: January 2000 to August 2002
A priori sample size estimation: yes
Sponsor: Aventis Pharma, and Finnish governmental grant
Role of sponsor: supplied experimental medication, but was not involved in the trial at any stage
Conflict of interest: many primary researchers have been consulted by trial sponsor
Identification number clinical trial: not reported
The FINLEVO Trial 2006 specified treatment regimens for patients under 60/50 kg and patients over
60/50 kg, but does not specify the exact treatment pattern for people who are either 60 or 50 kg. We
contacted the main author for clarification, but as of yet have received no answer.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Randomization was done blindly and separately at each study loca-
tion..." (page 180)
Comment: insufficient information about the sequence generation process to
permit judgement of 'low risk' or 'high risk'
Allocation concealment
(selection bias)
Unclear risk Insufficient information about the sequence generation process to permit





High risk Quote: "...the treatments were open for the investigator and the patient" (page
180)
Blinding of outcome as-
sessment (detection bias)
Unclear risk Trial was designed to assess the efficacy of antibiotics in Staphylococcus au-
reus bacteraemia. There was no separate information on this outcome in peo-
FINLEVO Trial 2006  (Continued)
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Cure ple with endocarditis; insufficient information to permit judgement of 'low
risk' or 'high risk'.
Blinding of outcome as-
sessment (detection bias)
All-cause mortality
Low risk No blinding of outcome assessment, but the review authors judged that the
outcome measurements were not likely to be influenced by lack of blinding.
Blinding of outcome as-
sessment (detection bias)
Adverse events
Unclear risk Insufficient information about blinding outcome assessment process to permit
judgement of 'low risk' or 'high risk' in participants with endocarditis.
Blinding of outcome as-
sessment (detection bias)
Incidence of septic em-
bolism
Unclear risk Trial was designed to assess the efficacy of antibiotics in Staphylococcus au-
reus bacteraemia. There was no separate information on the incidence of sep-
tic embolism in participants with endocarditis; insufficient information to per-
mit judgement of 'low risk' or 'high risk'.




Unclear risk Insufficient information about the sequence generation process to permit
judgement of 'low risk' or 'high risk'
Blinding of outcome as-
sessment (detection bias)
Quality of life
Unclear risk Trial was designed for assessing efficacy of antibiotic in Staphylococcus aureus
bacteraemia. There was no information on quality of life in participants with
endocarditis; insufficient information to permit judgement of 'low risk' or 'high
risk'.
Blinding of outcome as-
sessment (detection bias)
Need for cardiac surgical
interventions
Unclear risk Insufficient information about the sequence generation process to permit
judgement of 'low risk' or 'high risk'




Unclear risk Trial was designed to assess the efficacy of antibiotics in Staphylococcus au-
reus bacteraemia. There was no information on indication of cardiac surgery in
participants with endocarditis; insufficient information to permit judgement of
'low risk' or 'high risk'.
Blinding of outcome as-
sessment (detection bias)
Uncontrolled infection
Unclear risk Insufficient information about the sequence generation process to permit
judgement of 'low risk' or 'high risk'
Blinding of outcome as-
sessment (detection bias)
Relapse
Unclear risk Trial was designed to assess the efficacy of antibiotics in Staphylococcus au-
reus bacteraemia. There was no information on relapse in participants with





Unclear risk Trial was designed to assess the efficacy of antibiotics in Staphylococcus au-
reus bacteraemia rather than in infective endocarditis, therefore there was in-
sufficient information to permit judgement of 'low risk' or 'high risk'.
Selective reporting (re-
porting bias)
Unclear risk Trial was designed to assess the efficacy of antibiotics in Staphylococcus au-
reus bacteraemia. There was no information on selective reporting in partici-
pants with endocarditis; insufficient information to permit judgement of 'low
risk' or 'high risk'.
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Study characteristics
Methods Design: parallel (3 groups)
Multicentre study: no
Country: Spain
Follow-up period: at least 12 weeks after completion of therapy
Unit of randomisation: participants
Unit of analysis: participants
Duke's criteria for diagnosis of infective endocarditis: yes
Participants People with native valves





• Vancomycin-gentamicin: 1/11 (9%) by extrapulmonary foci






• Overall: 30.5 (range 18 to 43) years
• Cloxacillin-gentamicin: 28 (range 23 to 38) years
• Vancomycin-gentamicin: 25 (range 18 to 31) years







• Cloxacillin-gentamicin: 2 (18%)
• Vancomycin-gentamicin: 2 (20%)
• Teicoplanin-gentamicin: 1 (10%)
HIV infection (n/%)
• Cloxacillin-gentamicin: 8 (73%)
• Vancomycin-gentamicin: 5 (71%)
• Teicoplanin-gentamicin: 5 (62.5%)
CD4 count (mean)
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• Cloxacillin-gentamicin: 300 (range 129 to 600) cells/mm3
• Vancomycin-gentamicin: 210 (range 120 to 500) cells/mm3
• Teicoplanin-gentamicin: 243 (range 130 to 378) cells/mm3
White blood cells count (mean)
• Cloxacillin-gentamicin: 7775 (range 3800 to 10,300) cells/mm3
• Vancomycin-gentamicin: 6730 (range 2300 to 14,500) cells/mm3
• Teicoplanin-gentamicin: 8160 (range 5400 to 16,300) cells/mm3
Neutrophil count (mean)
• Cloxacillin-gentamicin: 5998 (range 4200 to 8100) cells/mm3
• Vancomycin-gentamicin: 5040 (range 1400 to 11,730) cells/mm3
• Teicoplanin-gentamicin: 6800 (range 4060 to 14,100) cells/mm3
Inclusion criteria
• Parenteral drug abusers
• Fever
• Isolation of methicillin-susceptible Staphylococcus aureus from ≥ 2 cultures of blood samples
• Septic pulmonary embolisation
• Tricuspid regurgitation murmur
• Echocardiographic evidence of endocarditis (intracardiac mass on valve or supporting structures, ab-
scess, or nodular tricuspid thickening)
Exclusion criteria
• Isolation of methicillin-resistant Staphylococcus aureus from cultures of blood samples
• Allergy to the antibiotics used
• Extrapulmonary metastatic focus at enrolment or developed within the first 48 hours of therapy
• Serum creatinine level > 220 nmol/L (> 2.5 mg/dL)
• LeO-side endocarditis observed on an echocardiogram
• Presence of non-biological valvular prosthesis or long-term catheter
• Polymicrobial infections
• Pregnancy
• Receipt of effective antimicrobial treatment during the 72 hours prior to the study period
Interventions Cloxacillin-gentamicin: cloxacillin: 2 g every 4 hours, IV + gentamicin 1.5 mg/kg every 8 hours
Vancomycin-gentamicin: vancomycin: 500 mg every 6 hours, IV + gentamicin 1.5 mg/kg every 8 hours
Teicoplanin-gentamicin: teicoplanin: 12 mg/kg every 24 hours, with a loading dose of 24 mg/kg on first
day + gentamicin 1.5 mg/kg every 8 hours
Treatment duration: 14 days
Outcomes Outcomes were not classified as primary or secondary.
• Efficacy (response to therapy) by:
* cure;
* clinical failure: definition;
* microbiological failure;
* microbiological relapse;
* duration of fever while receiving therapy.
• Adverse effects
Notes Conduction date: not reported
Fortún 2001  (Continued)
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A priori sample size estimation: no
Sponsor: not reported
Role of sponsor: not reported
Conflict of interest: not declared
Identification number clinical trial: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: " ...randomized ..." (page 120)
Comment: insufficient information about the sequence generation process to
permit judgement of 'low risk' or 'high risk'
Allocation concealment
(selection bias)
Unclear risk Insufficient information about the allocation concealment process to permit





High risk Quote: "...open..." (pages 120 and 123)
Blinding of outcome as-
sessment (detection bias)
Cure
Low risk No blinding of outcome assessment, but the review authors judged that the
outcome measure (cure) was not likely to be influenced by lack of blinding.
Blinding of outcome as-
sessment (detection bias)
All-cause mortality
Low risk No blinding of outcome assessment, but the review authors judged that the
outcome measure (all-cause mortality) was not likely to be influenced by lack
of blinding.
Blinding of outcome as-
sessment (detection bias)
Adverse events
Low risk No blinding of outcome assessment, but the review authors judged that the
outcome measure (adverse events) was not likely to be influenced by lack of
blinding.
Blinding of outcome as-
sessment (detection bias)
Incidence of septic em-
bolism
Unclear risk Trial did not assess incidence of septic embolism.




Unclear risk Trial did not assess incidence of congestive heart failure.
Blinding of outcome as-
sessment (detection bias)
Quality of life
Unclear risk Trial did not assess quality of life.
Blinding of outcome as-
sessment (detection bias)
Need for cardiac surgical
interventions
Unclear risk Trial did not assess need for cardiac surgical interventions.
Blinding of outcome as-
sessment (detection bias)
Unclear risk Trial did not assess indication of cardiac surgery.
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Indication of cardiac
surgery
Blinding of outcome as-
sessment (detection bias)
Uncontrolled infection
Unclear risk Trial did not assess uncontrolled infection.
Blinding of outcome as-
sessment (detection bias)
Relapse
Low risk No blinding of outcome assessment, but the review authors judged that the




Low risk Data for primary outcome available for 31/34 (91%) of the randomised sample,
with balanced reasons for withdrawals or losses to follow-up.
Selective reporting (re-
porting bias)
Unclear risk All the outcomes listed in the Methods section were described in the Results
section.
Trial authors did not mention data of clinical key outcomes such as mortality
and heart failure.





Methods Design: parallel (2 arms)
Multicentre: yes (44 sites)
Countries: USA
Follow-up period: 42 days
Unit of randomisation: participants
Unit of analysis: participants
Duke's criteria for diagnosis of infective endocarditis: yes
Participants People with native and prosthetic valve
Enrolled and randomised: 246
• Daptomycin: 126
• Standard therapy: 120
Lost postrandomisation: 10
• Daptomycin: 6
• Standard therapy: 4
Analysed: 235/246 (96%)
• Daptomycin: 120
• Standard therapy: 115
Age: not reported separately for the endocarditis group
Fowler 2006 
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Gender (male): not reported separately for the endocarditis group
Definitive endocarditis (baseline diagnosis) (n/%)
• Daptomycin: 17 (14.2%)
• Standard therapy: 20 (61.7%)
LeO-sided endocarditis (final diagnosis) (n/%)
• Daptomycin: 9 (7.5%)
• Standard therapy: 9 (7.8%)
Inclusion criteria:
• ≥ 18 years of age






• Renal failure with creatinine clearance < 30 mL/minute
• Initial Staphylococcus aureus blood culture outside the 2-day window
• Inability to provide consent or unlikely to comply with study-related procedures
• Presence of an intravascular material (excluding cardiac stents) not intended to be removed within
4 calendar days
• Receipt of non-study antibiotics potentially effective against Staphylococcus aureus
• High likelihood of death or valve replacement surgery in the first 3 days following randomisation
• Refractory shock, significant hepatic insufficiency, or severe leukopenia
• Weight < 50 kg or > 150 kg
• Allergy to vancomycin or penicillin
• Infection with Staphylococcus aureus with reduced susceptibility to vancomycin (minimum inhibitory
concentration > 4 μg/mL)
Interventions Experimental: daptomycin: 6 mg/kg body weight, once daily, IV (1 participant also received gentamicin
1 mg/kg given every 8 hours for the first 4 days)
Control: standard treatment with either:
• vancomycin 1 g, every 12 hours with appropriate dose adjustment with gentamicin 1 mg/kg given
every 8 hours for the first 4 days; OR
• antistaphylococcal penicillin (nafcillin, oxacillin, or flucloxacillin) 2 g given every 4 hours, depending
on the susceptibility of the causative strain to methicillin with gentamicin 1 mg/kg given every 8 hours
for the first 4 days.
Treatment duration: 4 to 6 weeks was determined by the investigator on the basis of the working
group. Mean treatment durations were 14 days in daptomycin group and 15 days in standard treatment
group.
Outcomes Primary
• Failure at this visit (42 days) was defined as:
• clinical failure: no response to the study drug on the basis of ongoing signs and symptoms of in-
fection;
• microbiological failure: persistent or relapsing Staphylococcus aureus infection;
• death;
• failure to obtain blood culture;
Fowler 2006  (Continued)
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• receipt of potentially effective non-study antibiotics (any antibiotic received during or after study
drug therapy that may have influenced the outcome);
• premature discontinuation of the study medication because of clinical failure, microbiological fail-
ure, or an adverse event.
• Adverse events: coded using the Medical Dictionary for Regulatory Activities (MedDRA) (Version 6.0)
Notes Conduction date: 28 August 2002 to 16 February 2005
A priori sample size estimation: yes (page 655)
Sponsor: Cubist Pharmaceuticals
Role of sponsor: study was designed and analysed by the sponsor (page 656)
Conflict of interest: many trials authors were consultants or employees of Cubist Pharmaceuticals
(pages 654, 656)
Identifier number: ClinicalTrials.gov ID NCT00093067 (page 653)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "... this centralized computer-generated schedule was designed to









High risk Quote: "open-label" (page 654)
Blinding of outcome as-
sessment (detection bias)
Cure
Low risk No blinding of outcome assessment, but the review authors judged that the
outcome measure (cure) was not likely to be influenced by lack of blinding.
Blinding of outcome as-
sessment (detection bias)
All-cause mortality
Unclear risk Trial did not assess all-cause mortality.
Blinding of outcome as-
sessment (detection bias)
Adverse events
Unclear risk Trial did not assess adverse events.
Blinding of outcome as-
sessment (detection bias)
Incidence of septic em-
bolism
Unclear risk Trial did not assess incidence of septic embolism.




Unclear risk Trial did not assess incidence of congestive heart failure.
Blinding of outcome as-
sessment (detection bias)
Unclear risk Trial did not assess quality of life.
Fowler 2006  (Continued)
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Quality of life
Blinding of outcome as-
sessment (detection bias)
Need for cardiac surgical
interventions
Unclear risk Trial did not assess need for cardiac surgical interventions.




Unclear risk Trial did not assess indication of cardiac surgery.
Blinding of outcome as-
sessment (detection bias)
Uncontrolled infection
Low risk No blinding of outcome assessment, but the review authors judged that the
outcome measure (uncontrolled infection) was not likely to be influenced by
lack of blinding.
Blinding of outcome as-
sessment (detection bias)
Relapse




Low risk Participants lost postrandomisation not receiving treatment: 10/246 (4%)
Participants lost receiving treatment: 1/236 (0.4%)
Selective reporting (re-
porting bias)
High risk Trial did no report all-cause mortality and adverse events.





Methods Design: parallel (2 arms)
Multicentre: yes (10 sites)
Countries: Spain
Follow-up period: 6 weeks
Unit of randomisation: participants
Unit of analysis: participants
Participants • Type: complicated bacteraemia and endocarditis due to methicillin-resistant Staphylococcus aureus
• Randomised: 15
(The following data relate only to those participants with infective endocarditis (IE): 8)
Fosfomycin plus imipenem: 4 (2 native valve IE, 2 prosthetic valve IE)
Vancomycin: 4 (1 native valve IE, 3 pacemaker IE)
Age (years, mean (SD))
• Fosfomycin plus imipenem: 84 (3.3)
• Vancomycin: 78 (6.34)
Pericas 2018 
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Sex (male):
• Fosfomycin plus imipenem: 75% (3/4)
• Vancomycin: 25% (1/4)
Source
• Fosfomycin plus imipenem: vascular (1), urinary (1), cutaneous (1), unknown (1)
• Vancomycin: vascular (2) and unknown (2)
Acquisition
• Fosfomycin plus imipenem: non-nosocomial healthcare-associated (2) and nosocomial (2)
• Vancomycin: non-nosocomial healthcare-associated (2) and nosocomial (2)
Days of bacteraemia until study initiation (media)
• Fosfomycin plus imipenem: 3.25 (0.95)
• Vancomycin: 1 (all participants had 1 day)
Days of study treatment (mean (SD), median)
• Fosfomycin plus imipenem: 18.25 (22.02), 9
• Vancomycin: 35.75 (7.5), 37
Inclusion criteria: adults with suspected or confirmed methicillin-resistant Staphylococcus aureus in-
fective endocarditis (IE; native or prosthetic valve, pacemaker/defibrillator) according to the modified
Duke criteria, prosthetic vascular graO infection or complicated bacteraemia (septic thrombophlebitis,
soO tissue-skin infection, pneumonia, osteomyelitis, or unknown source)
Excusion criteria:
• Aged under 18 years
• Antibiotics with anti-methicillin-resistant Staphylococcus aureus activity received for > 72 h
• Shock or hypotension
• Urgent surgery needed
• Active intravenous drug use
• Vancomycin trough levels > 15 µg/mL at 72 h in participants with chronic renal insufficiency or
haemodialysis
• Methicillin-resistant Staphylococcus aureus strains with fosfomycin minimum inhibitory concentra-
tion (MIC) > 64 mg/L or vancomycin MIC ≥ 2 mg/L
• Known allergy to vancomycin, fosfomycin, or imipenem
Interventions • Intervention: fosfomycin (2 g/6 h IV) plus imipenem (1 g/6 h IV), adjusted for renal function
• Control: vancomycin (30 to 45 mg/kg daily IV divided into 2 to 3 doses, trough levels ≥ 15 mg/L)
Note: if the participant developed either treatment failure or renal failure with vancomycin, he/she was
switched to the other comparison group.
• Treatment duration:
• Complicated bacteraemia with rapid control of the source and negative first control complicated
bacteraemia: 2 weeks
• Non-complicated native valve infective endocarditis and pacemaker/defibrillator infective endo-
carditis or non-rapidly controlled complicated bacteraemia: 4 weeks
• Prosthetic valve infective endocarditis, complicated native infective endocarditis, and complicat-
ed bacteraemia with osteomyelitis: 6 weeks
Outcomes Trial authors did not classify the outcomes as primary or secondary. However, the trial reported data
on death, cure, adverse events including treatment-related adverse events, cardiac surgical interven-
tions, uncontrolled infection, and relapse of endocarditis.
Pericas 2018  (Continued)
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Notes Conduction date: October 2009 to December 2014
A priori sample size estimation: yes
This trial was stopped early due to difficulties in recruiting participants.
Support: Ministerio de Sanidad y Consumo of Spain (Fondo de Investigaciones Sanitarias, Instituto de
Salud Carlos III, Madrid, Spain, several grants from public Spanish entities).
Role of support: not stated
Conflict of interest: 1 author has received consulting honoraria or research grants, or both, from Abb-
Vie, Bristol-Myers Squibb, Cubist, Novartis, Gilead Sciences, and ViiV.
Identifier number: ClinicalTrials.gov ID NCT00871104
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote "...randomized clinical trial..." (page 673)




Unclear risk Quote "...randomized clinical trial..." (page 673)






High risk Quote "open-label" (page 673)
Blinding of outcome as-
sessment (detection bias)
Cure
Unclear risk Comment: insufficient information to permit judgement of 'low risk' or 'high
risk'
Blinding of outcome as-
sessment (detection bias)
All-cause mortality
Unclear risk Comment: insufficient information to permit judgement of 'low risk' or 'high
risk'
Blinding of outcome as-
sessment (detection bias)
Adverse events
Unclear risk Comment: insufficient information to permit judgement of 'low risk' or 'high
risk'
Blinding of outcome as-
sessment (detection bias)
Incidence of septic em-
bolism
Unclear risk Comment: insufficient information to permit judgement of 'low risk' or 'high
risk'




Unclear risk Comment: insufficient information to permit judgement of 'low risk' or 'high
risk'
Blinding of outcome as-
sessment (detection bias)
Quality of life
Unclear risk Trial did not assess quality of life.
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Blinding of outcome as-
sessment (detection bias)
Need for cardiac surgical
interventions
Unclear risk Comment: insufficient information to permit judgement of 'low risk' or 'high
risk'




Unclear risk Comment: insufficient information to permit judgement of 'low risk' or 'high
risk'
Blinding of outcome as-
sessment (detection bias)
Uncontrolled infection
Unclear risk Comment: insufficient information to permit judgement of 'low risk' or 'high
risk'
Blinding of outcome as-
sessment (detection bias)
Relapse





Low risk Trial authors reported data from 8 participants with IE.
Selective reporting (re-
porting bias)
Low risk Trial authors reported relevant clinical endpoints.





Methods Design: parallel (2 arms)
Multicentre: yes (15 sites)
Countries: Denmark
Follow-up period: 6 months
Unit of randomisation: participants
Unit of analysis: participants
Type of randomised controlled trial: non-inferiority trial ("whether partial oral treatment was non-infe-
rior to conventional intravenous treatment")
Participants • Referred: 1954
• Enrolled: 400 endocarditis on the leO side of the heart
• Randomised:
• Conventional intravenous treatment: 199
• To a shiO to oral treatment: 201
• Age (years, mean (SD)):
• Conventional intravenous treatment: 67.3 (12)
• To a shiO to oral treatment: 67.6 (12.6)
• Sex (male):
• Conventional intravenous treatment: 74.87% (149/199)
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• To a shiO to oral treatment: 79.10% (159/201)
• Pathogen:
• Conventional intravenous treatment: Streptococcus (52.3%), Enterococcus faecalis (23.1%), Sta-
phylococcus aureus (20.1%), and coagulase-negative staphylococci (5.0%)
• To a shiO to oral treatment: Streptococcus (45.8%), Enterococcus faecalis (25.4%), Staphylococcus
aureus (23.4%), and coagulase-negative staphylococci (6.5%)
• Pre-existing prosthesis, implant, or cardiac disease:
• Conventional intravenous treatment: prosthetic heart valve (26.6%), pacemaker (7.5%), other
known valve disease (41.2%)
• To a shiO to oral treatment: prosthetic heart valve (26.9%), pacemaker (10%), other known valve
disease (44.8%)
• Cardiac involvement at randomisation:
• Conventional intravenous treatment: mitral-valve endocarditis (32.7%), aortic-valve endocarditis
(54.8%), mitral-valve and aortic-valve endocarditis (11.6%), pacemaker endocarditis (3.0%), and
vegetation size > 9 mm (3.5%)
• To a shiO to oral treatment: mitral-valve endocarditis (35.8%), aortic-valve endocarditis (54.2%),
mitral-valve and aortic-valve endocarditis (10.0%), pacemaker endocarditis (4.0%), and vegetation
size > 9 mm (5.5%)
• Coexisting condition or risk factor:
• Conventional intravenous treatment: diabetes (18.1%), renal failure (12.6%), dialysis (6.5%), COPD
(8.5%), liver disease (3.5%), cancer (7.0%), and intravenous drug use (1.5%)
• To a shiO to oral treatment: diabetes (15.4%), renal failure (10.4%), dialysis (7.5%), COPD (4.5%),
liver disease (3.0%), cancer (9.0%), and intravenous drug use (1.0%)
• Inclusion criteria:
• LeO-sided endocarditis based on the Duke criteria
• Infected with 1 of the following micro-organisms: streptococci, Enterococcus faecalis, Staphylococ-
cus aureus, coagulase-negative staphylococci
• Adult participants (≥ 18 years)
• At least ≥ 10 days of appropriate parenteral antibiotic treatment overall, and at least 1 week of
appropriate parenteral treatment after valve surgery
• Temperature < 38.0 °C > 2 days
• C-reactive protein dropped to less than 25% of peak value or < 20 mg/L, and white blood cell count
less than 15 x 109/L during antibiotic treatment
• No sign of abscess formation revealed by echocardiography
• Transthoracic and trans-oesophageal echocardiography performed within 48 hours of randomisa-
tion
• Exclusion criteria:
• Body mass index > 40
• Concomitant infection requiring intravenous antibiotic therapy
• Inability to give informed consent to participation
• Suspicion of reduced absorption of oral treatment due to abdominal disorder
• Reduced compliance
Interventions • Oral treatment: the composition, doses, and duration of different oral regimens is shown in Appendix
6.
• Conventional intravenous treatment: based on the guidelines of the European Society of Cardiology
(Habib 2015), with modifications endorsed by the Danish Society of Cardiology (Moser 2017)
No details were provided regarding the conventional intravenous therapy regimens.
Outcomes Primary: composite of all-cause mortality, unplanned cardiac surgery, clinically evident embolic
events, or relapse of bacteraemia with the primary pathogen (detected in blood cultures obtained dur-
ing follow-up or for clinical reasons) from randomisation through 6 months after antibiotic treatment
was completed
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Trial assessed and reported adverse events.
Notes Identifier number: ClinicalTrials.gov ID NCT01375257
Conduction date: 15 July 2011 to 30 August 2017
A priori sample size estimation: yes
Support: the Danish Heart Foundation and the Capital Regions Research Council, the Hartmann’s
Foundation, Svend Aage Andersens Foundation, and the Novo Nordisk Foundation
Role of support: not stated
Conflict of interest: 1 author has received consulting honoraria or research grants, or both, from Bayer.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote "Randomization was performed with the use of a Web-based system,




Low risk Quote "Randomization was performed with the use of a Web-based system,






High risk Quote "...unblinded..." (page 416)
Blinding of outcome as-
sessment (detection bias)
Cure
Unclear risk This outcome was not mentioned.
Blinding of outcome as-
sessment (detection bias)
All-cause mortality
Low risk Quote "A clinical-event adjudication committee, whose members were un-
aware of the treatment assignments, adjudicated the prespecified clinical out-
comes. The committee consisted of experienced cardiologists and a specialist
in infectious diseases." (page 417)
Blinding of outcome as-
sessment (detection bias)
Adverse events
Low risk Quote "A clinical-event adjudication committee, whose members were un-
aware of the treatment assignments, adjudicated the prespecified clinical out-
comes. The committee consisted of experienced cardiologists and a specialist
in infectious diseases." (page 417)
Blinding of outcome as-
sessment (detection bias)
Incidence of septic em-
bolism
Low risk Quote "A clinical-event adjudication committee, whose members were un-
aware of the treatment assignments, adjudicated the prespecified clinical out-
comes. The committee consisted of experienced cardiologists and a specialist
in infectious diseases." (page 417)




Low risk Quote "A clinical-event adjudication committee, whose members were un-
aware of the treatment assignments, adjudicated the prespecified clinical out-
comes. The committee consisted of experienced cardiologists and a specialist
in infectious diseases." (page 417)
Blinding of outcome as-
sessment (detection bias)
Quality of life
Unclear risk This outcome was not mentioned.
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Blinding of outcome as-
sessment (detection bias)
Need for cardiac surgical
interventions
Low risk Quote "A clinical-event adjudication committee, whose members were un-
aware of the treatment assignments, adjudicated the prespecified clinical out-
comes. The committee consisted of experienced cardiologists and a specialist
in infectious diseases." (page 417)




Low risk Quote "A clinical-event adjudication committee, whose members were un-
aware of the treatment assignments, adjudicated the prespecified clinical out-
comes. The committee consisted of experienced cardiologists and a specialist
in infectious diseases." (page 417)
Blinding of outcome as-
sessment (detection bias)
Uncontrolled infection
Unclear risk This outcome was not mentioned.
Blinding of outcome as-
sessment (detection bias)
Relapse
Low risk Quote "A clinical-event adjudication committee, whose members were un-
aware of the treatment assignments, adjudicated the prespecified clinical out-
comes. The committee consisted of experienced cardiologists and a specialist




Low risk No participants were lost to follow-up.
Selective reporting (re-
porting bias)
Low risk Trial reported relevant clinical outcomes.





Methods Design: parallel (2 groups)
Multicentre study: yes (9 sites)
Country: USA
Follow-up period: 3 months
Unit of randomisation: participants
Unit of analysis: participants
Duke's criteria for diagnosis of infective endocarditis: yes
Participants People with ceftriaxone-susceptible Streptococcus viridans or Streptococcus bovis endocarditis
People with native valve
Enrolled and randomised: 67
• Ceftriaxone: 33
• Ceftriaxone + gentamicin: 3
Analysed for clinical efficacy: 51
• Ceftriaxone: 26
• Ceftriaxone + gentamicin: 25
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Age (mean)
• Ceftriaxone: 52.5 (SD 17.8) (range 18 to 87) years
• Ceftriaxone + gentamicin: 59.5 (SD 15.5) (range 27 to 92) years
Gender (male)
• Ceftriaxone: not reported
• Ceftriaxone + gentamicin: not reported
• Total group: 41 (80.3%)
Previous endocarditis
• Ceftriaxone: 4 (15.3%)
• Ceftriaxone + gentamicin: 1 (4%)
History of rheumatic heart disease
• Ceftriaxone: 3 (11.5%)
• Ceftriaxone + gentamicin: 3 (12%)
Inclusion criteria
• Aged ≥ 18 years
• Received < 72 hours of parenteral antibiotic therapy before enrolment
• Provided written informed consent
Exclusion criteria
• Presence of aetiological agents other than ceftriaxone-susceptible viridans streptococci or S bovis
• Hypersensitivity to cephalosporins or aminoglycosides
• Prior treatment with antibiotics for > 72 hours
• New York Heart Association class IV heart failure
• Need for therapy for > 2 weeks
• Moderate-to-severe renal dysfunction (serum creatinine clearance of < 20 mL/minute)
• Prosthetic valve endocarditis
• Clinically apparent moderate-to-severe hearing loss or vestibular dysfunction
• Neutropenia (absolute neutrophil count < 1000/mm3)
Interventions Experimental: ceftriaxone 2 g once daily for 4 weeks, IV + gentamicin 3 mg/kg IV once daily for 2 weeks
Control: ceftriaxone 2 g once daily, IV
Infusion time: 30 to 60 minutes
Co-intervention: not reported
Treatment duration: 2 to 4 weeks
Outcomes Outcomes were not classified as primary or secondary.




Notes Conduction date: 29 January 1992 to 22 December 1996
A priori sample size estimation: no
Sponsor: Roche
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Role of sponsor: not reported
Conflict of interest: not declared
Identification number clinical trial: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Patients were assigned randomly" (page 1471)









High risk Quote: "This randomised, multicenter, open-label study" (page 1470)
Blinding of outcome as-
sessment (detection bias)
Cure
Low risk The review authors judged that the outcome measure (cure) was not likely to
be influenced by lack of blinding.
Blinding of outcome as-
sessment (detection bias)
All-cause mortality
Unclear risk The trial did not assess all-cause mortality.
Blinding of outcome as-
sessment (detection bias)
Adverse events
Low risk The review authors judged that the outcome measure (adverse events) was
not likely to be influenced by lack of blinding.
Blinding of outcome as-
sessment (detection bias)
Incidence of septic em-
bolism
Unclear risk The trial did not assess incidence of septic embolism.




Unclear risk The trial did not assess incidence of congestive heart failure.
Blinding of outcome as-
sessment (detection bias)
Quality of life
Unclear risk The trial did not assess quality of life.
Blinding of outcome as-
sessment (detection bias)
Need for cardiac surgical
interventions
Low risk The review authors judged that the outcome measure (need for cardiac surgi-
cal interventions) was not likely to be influenced by lack of blinding.




Low risk The review authors judged that the outcome measure (indication of cardiac
surgery) was not likely to be influenced by lack of blinding.
Sexton 1998  (Continued)
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Blinding of outcome as-
sessment (detection bias)
Uncontrolled infection
Low risk The review authors judged that the outcome measure (uncontrolled infection)
was not likely to be influenced by lack of blinding.
Blinding of outcome as-
sessment (detection bias)
Relapse
Unclear risk The review authors judged that the outcome measure (relapse) was not likely




High risk Loss postrandomisation: 51/67 (24%)
• Ceftriaxone: 7 (21.2%)
• Ceftriaxone + gentamicin: 9 (26.47%)
Selective reporting (re-
porting bias)
High risk Trial did not mention all-cause mortality and other clinically relevant out-
comes.
Other bias High risk Design bias
Sexton 1998  (Continued)
COPD: chronic obstructive pulmonary disease
IV: intravenous
n: number of participants
SD: standard deviation
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Abrams 1979 Randomised clinical trial did not use Duke's criteria for diagnosis of infective endocarditis. It used
Von Reyn 1981 criteria.
Fortún 1995 Randomised clinical trial that did not use Duke's criteria for diagnosis of infective endocarditis
Gilbert 1991 Randomised clinical trial that did not use Duke's criteria for diagnosis of infective endocarditis
Greenman 1984 Randomised clinical trial that did not use Duke's criteria for diagnosis of infective endocarditis
Heldman 1996 Randomised clinical trial that did not use Duke's criteria for diagnosis of infective endocarditis
Korzeniowski 1982 Randomised clinical trial that did not use Duke's criteria for diagnosis of infective endocarditis
Levine 1991 Randomised clinical trial that did not use Duke's criteria for diagnosis of infective endocarditis
Markowitz 1992 Randomised clinical trial that did not use Duke's criteria for diagnosis of infective endocarditis
Ribera 1996 Randomised clinical trial that did not use Duke's criteria for diagnosis of infective endocarditis
Stamboulian 1991 Randomised clinical trial that did not use Duke's criteria for diagnosis of infective endocarditis
 
Characteristics of ongoing studies [ordered by study ID]
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Study name An open labelled, double arm, randomized, multicentric, prospective and comparative, phase-III
trial to evaluate the safety and efficacy of fixed dose combination of ceftriaxone and vancomycin
injection versus vancomycin injection in subjects with various bacterial infections
Methods Randomised, parallel-group, active-controlled trial
Method of generating randomisation sequence: computer-generated randomisation
Method of allocation concealment: not applicable
Blinding and masking: not applicable
Phase 3
Participants • Age minimum: not reported
• Age maximum: not reported
• Gender: not reported
• Inclusion criteria: all participants aged between 18 and 70 years
• Diagnosed participants of infectious disease (on clinical evaluation)
• Participants willing to give informed consent
• Participant suffering from any of the following infections: lower respiratory tract infections,
skin and skin structure infections, endocarditis, bacterial meningitis, and bone infection
• Exclusion criteria:
• History of hypersensitivity reaction or any specific contraindication to penicillin group of drugs
or ceftriaxone or vancomycin
• Presence of hepatic or renal disorder
• Pregnancy and/or lactation
Interventions • Intervention: vancomycin (2 g divided either as 500 mg every 6 hours or 1 g every 12 hours) and
ceftriaxone combined (6 g IV in 2 equally divided slow doses, depending on the severity of disease)
• Control intervention: vancomycin (2 g divided either as 500 mg every 6 hours or 1 g every 12 hours)
Outcomes Primary: efficacy of a 3.0 g ceftriaxone and vancomycin injection versus 1.0 g vancomycin injection
in participants with mild-to-severe bacterial infections
Secondary: safety of the test and comparative product
Note: the protocol authors did not report primary outcomes, instead reporting a primary objective
rather than a measurement of efficacy.
Starting date 7 May 2008
Contact information Dr Namit Saraf (Senior Doctor) (drnamitsaraf@rediffmail.com). Orthopaedics Department, Ansari
Road AIIMS 110029, New Delhi, DELHI, India
Mahesh Mudgal: Flat No: 90, Pocket A Sector - 14, Dwarka 110029 New Delhi, DELHI, India





Study name A multicenter, double-blind, randomized, comparative study of the safety, tolerability, efficacy,
and pharmacokinetics of CF-301 versus placebo in addition to standard-of-care antibacterial ther-
apy for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bac-
teremia) including endocarditis
Methods Controlled, randomised, double-blind, parallel group, placebo
EUCTR 2016-003059-31 
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Arms: 2
Phase: phase II
Participants • Male or female
• Age: ≥ 18 years or older
• Inclusion criteria: known or suspected endocarditis by modified Duke criteria and/or known or
suspected complicated Staphylococcus aureus, and several other inclusion criteria
• Exclusion criteria: several
Interventions CF-301, solution for infusion
Placebo: solution for infusion, intravenous use
Standard-of-care antibacterial therapy
Outcomes Primary:
• Safety and tolerability of CF-301 versus placebo in addition to standard-of-care antibacterial ther-
apy
• Clinical outcome at Day 14 after CF-301/placebo administration
• Pharmacokinetic parameters of CF-301
Secondary endpoint(s):
• Clinical outcome at Day 7 after CF301/placebo administration
• Clinical outcome at the end of standard-of-care antibacterial therapy, and at test of cure, and 28
days after test of cure
• Microbiological response
• Microbiological outcome
Starting date 27 Octuber 2017
Contact information Clinical Development Corporation





Study name A randomized, double-blind, multi-center study to establish the efficacy and safety of ceftobiprole
medocaril compared to daptomycin in the treatment of Staphylococcus aureus bacteremia, includ-
ing infective endocarditis
Methods Controlled, randomised, double-blind, parallel group
Phase: phase III
International multicentre
Participants Age minimum: 18 years
Age maximum: not reported
Female: yes
Male: yes
Several inclusion and exclusion criteria
EUCTR 2017-001699-43 
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Outcomes • Primary endpoint(s): overall success at the PTE visit (Day 70 ± 5 days postrandomisation): the pri-
mary endpoint will be tested for the non-inferiority of ceftobiprole versus daptomycin using a
non-inferiority margin of 15%. Several criteria for assessing overall success.
• Secondary objective: to compare ceftobiprole with daptomycin with respect to several criteria
Starting date 13 December 2018
Contact information Alain Bobillier (alain.bobillier@basilea.com)
Affiliation: Basilea Pharmaceutica International Ltd




Study name Evaluación de la eficacia y la seguridad de la combinación de fosfomicina (F) e imipenem (I) para el
tratamiento de la endocarditis infecciosa (EI) sobre válvula nativa o protésica por Staphylococcus
aureus resistente a meticilina (SARM)
Methods Not reported
Participants Age: adults, elderly
Sex: male or female
Interventions Not reported
Outcomes Not reported
Starting date 23 September 2009





Study name An open-label randomized controlled trial of ampicillin/cloxacillin and ceftriaxone for empirical
treatment of infective endocarditis
Methods Interventional
Parallel, randomised
Participants • Inclusion criteria:
• Patients with confirmed or suspected diagnosis of infective endocarditis based on modified
Duke's criteria, who need to start empirical treatment waiting for the result of blood cultures
• Exclusion criteria:
JPRN-UMIN 000032006 
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• Causative micro-organism already confirmed
• History of allergy or contraindication of penicillin, cephalosporins, and aminoglycoside
• History of prosthetic valve replacement within 1 year
• eGFR less than 50 mL/min
• White blood cells less than 1000/μL, when physicians in charge chose another treatment reg-
imen
• Age minimum: 20 years
• Age maximum: not applicable
• Gender: male and female
Interventions • Intervention: ampicillin/cloxacillin 4 g every 4 hours IV maximum for 6 weeks plus gentamicin 3
mg/kg every 4 hours IV maximum for 2 weeks
• Control: ceftriaxone 2 g every 4 hours IV maximum for 6 weeks plus gentamicin 3 mg/kg every 4
hours IV maximum for 2 weeks
Outcomes Primary:
• Outcome of infective endocarditis at the end of antimicrobial treatment
Secondary:
• Days for defervescence less than 37 °C
• Days of hospitalisation
• Outcome at discharge
• Necessity of surgery during hospitalisation
• Outcome of infective endocarditis 3 months after the end of antimicrobial treatment
• Adverse events on skin, blood, liver, and kidney
Starting date 2 April 2018
Contact information Primary sponsor: Juntendo University
Contacts: Toshio Naito (naito@juntendo.ac.jp) and Yuki Uehara (yuuehara@juntendo.ac.jp)
Affiliation Juntendo University Faculty of Medicine Department of General Medicine
Notes upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036524




Study name A phase 4 multicenter, randomized, double blind study to describe the efficacy and safety of cu-
bicin (Daptomycin for Injection) with and without initial gentamicin combination therapy in the
treatment of Staphylococcus aureus infective endocarditis
Methods Interventional, randomised, parallel assignment, and double-blind (participant, investigator)
Phase IV
Participants Estimated enrolment: 24
Inclusion criteria:
• Written informed consent has been obtained
• Men or women ≥ 18 years
• History of drug abuse within the past 3 months or recent needle track marks
• Definite or possible infective endocarditis according to the modified Duke's criteria
NCT00638157 
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• 2 blood cultures positive for Staphylococcus aureus obtained within 96 hours prior to first dose
of study medication acquired by fresh venepuncture using aseptic technique and analysed at the
local laboratory
Exclusion criteria:
• Intravascular foreign material in place at the time that the positive blood culture was drawn
• High likelihood of leO infective endocarditis as indicate
• Prosthetic heart valve
• Baseline creatinine clearance of < 30 mL/minute
• Baseline creatinine phosphokinase value 5 x upper limit of normal in conjunction with symptoms
of myalgia or baseline creatine phosphokinase value 10 x upper limit of normal without symptoms
• Alanine aminotransferase > 5 x upper limit of normal
• Aspartate aminotransferase > 5 x upper limit of normal
• Moribund clinical condition
• Shock or hypotension
• Known pneumonia or osteomyelitis
• Polymicrobial infection or bacteraemia due to a pathogen other than Staphylococcus aureus
• Neutropenia (absolute neutrophil count < 0.5 x 103/μL) or lymphopenia (CD4 lymphocytes < 0.2
x 103/μL), or both
• Anticipated to require non-study antibiotics that may potentially be effective against Staphylo-
coccus aureus
• Prior gentamicin therapy > 1 day
• Documented history of significant allergy or intolerance to any of the study medications
• Unlikely to comply with study procedures
• Pregnant or nursing
• Female of childbearing potential and not willing to practice barrier methods of contraception
Interventions Experimental: daptomycin 6 mg/kg every 24 hours with concomitant initial gentamicin dosed for
the first 2 days of therapy
Control: daptomycin 6 mg/kg every 24 hours
Treatment duration: daptomycin will be 28 days. The duration of treatment for gentamicin will be 3
days.
Outcomes Primary:
• Clinically significant increases in serum creatinine by visit
Secondary:
• Clinical response
Starting date 13 February 2009
Contact information Sponsors and collaborators: Cubist Pharmaceuticals LLC (NCT00638157)
Notes Status: terminated due to "(commitment completed)" (accessed: 21 January 2016)
Primary completion date: November 2011 (final data collection date for primary outcome measure)
Sponsors and collaborators: Cubist Pharmaceuticals LLC
No publications provided.
Results first received: 4 March 2013
Last updated: 5 January 2016
NCT00638157  (Continued)
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Study name Official title: A phase 2 multicenter, randomized, double-blinded, study to describe the safety, ef-
ficacy, and pharmacokinetics of daptomycin 10 mg/kg/day and vancomycin for the treatment of
methicillin-resistant Staphylococcus aureus bacteraemia




• Written informed consent has been obtained
• ≥ 18 years
• Suspected methicillin-resistant Staphylococcus aureus bacteraemia determined by clinical judge-
ment or 2 sets of positive blood cultures
• Increased risk for a methicillin-resistant Staphylococcus aureus infection
Exclusion criteria:
• Received > 48 hours of vancomycin therapy in the 7 days prior to enrolment
• Received any systemic antibacterial agents potentially effective against methicillin-resistant Sta-
phylococcus aureus in the 7 days prior to enrolment
• Anticipated requirement of antibiotics potentially effective against methicillin-resistant Staphy-
lococcus aureus
• High likelihood of leO-sided infective endocarditis
• Known/suspected polymicrobial bacteraemia or infection including gram-negative infections
• Known pneumonia, osteomyelitis, or meningitis
• Intravascular foreign material unless material intended removed within 3 days
• Prosthetic heart valve
• Cardiac decompensation, valve damage, or both, such that high likelihood of valve replacement
surgery within first 3 days of study drug treatment
• Moribund clinical condition such that death likely within first 3 days of study drug treatment
• Shock or hypotension or oliguria unresponsive to fluids after 4 hours
• Received investigational drug within 30 days of study entry
• Received statins or other therapy associated with rhabdomyolysis within 2 days of study entry
• History of significant allergy or intolerance to vancomycin or daptomycin
• Infecting pathogen with confirmed reduced susceptibility to vancomycin
• Infecting pathogen with confirmed reduced susceptibility to daptomycin
• Creatinine clearance < 30 mL/minute
• Serum creatine phosphokinase ≥ 500 U/L
• Alanine transaminase or aspartate aminotransferase > 5 x upper limit of normal
• Total bilirubin ≥ 3.0 mg/dL
• Severe neutropenia or expected development of severe neutropenia during study
• Known or suspected HIV infection with a CD4+ T-cell count < 200/μL
• Unlikely to comply with study procedures or return for evaluations
• Body mass index ≥ 40 kg/m2
NCT00695903 
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• Pregnant or nursing
• Woman of childbearing potential not willing to practice barrier methods of contraception
Interventions Experimental: daptomycin 10 mg/kg IV every 24 hours
Control: vancomycin 15 mg/kg IV, dosed to maintain trough serum concentrations of 15 to 20 μg/
mL
Outcomes Primary:
• Number of participants with treatment-emergent creatine phosphokinase elevations
• Number of participants with elevated serum creatinine
Secondary:
• Number of participants with treatment cure at end of therapy visit
• Number of participants with treatment cure at test of cure/safety visit
Starting date 17 September 2008
Contact information Sponsors and collaborators: Cubist Pharmaceuticals LLC
Study director: Peter Pertel, MD; Cubist Pharmaceuticals LLC
Organisation: Cubist Pharmaceuticals
Email: ellie.hershberger@cubist.com
Notes Status: terminated due to lack of enrolment (accessed: 21 January 2016)




Study name A Phase 3 multicenter, randomized, open-label, clinical trial of telavancin versus standard intra-
venous therapy in the treatment of subjects with Staphylococcus aureus bacteremia Including Sta-
phylococcus aureus right-sided infective endocarditis
Methods Interventional, randomised, parallel assignment and open-label
Phase III
Participants Estimated enrolment: 248
Age: ≥ 18 years
Gender: men and women
Inclusion criteria:
• ≥ 18 years with ≥ 1 blood culture positive for S. aureus within 48 hours before randomisation
• ≥ 1 of the following signs or symptoms of bacteraemia: temperature ≥ 38.0 °C, white blood cells
> 10,000 or < 4000 cells/µL or > 10% immature neutrophils (bands), tachycardia (heart rate > 90
beats/minute), tachypnoea (respiratory rate > 20 breaths/minute), hypotension (systolic blood
pressure < 90 mmHg), signs or symptoms of localised catheter-related infection
NCT02208063 
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• At enrolment, participants must have:
* known right-sided infective endocarditis by modified Duke's criteria;
* known complicated bacteraemia, demonstrated as signs or symptoms of metastatic foci of
Staphylococcus aureus infection; or
* ≥ 1 risk factor for complicated bacteraemia.
Exclusion criteria:
• Treatment with any potentially effective (antistaphylococcal) systemic antibiotic for > 48 hours
within 7 days before randomisation. Exception: documented resistance to the prior systemic an-
tibacterial therapy
• Presence of any removable infection source (e.g. IV line, abscess) that will not be removed or de-
brided within 3 days after randomisation
• Presence of prosthetic joint or cardiac device (e.g. implantable cardioverter defibrillator, perma-
nent pacemaker, or prosthetic valve or cardiac valve support ring)
• Known or suspected leO-sided infective endocarditis, by modified Duke's criteria
• Known or suspected osteomyelitis (primary or embolic), or meningitis (primary). Note: evidence
of metastatic complications related to the primary infection such as right-sided endocarditis, sep-
tic arthritis, and septic pulmonary infarcts will be allowed.
Interventions Experimental: telavancin
Control: standard of care (vancomycin, daptomycin, synthetic penicillin or cefazolin)
Outcomes Primary:
• Clinical response (success or failure)
Secondary:
• Development of new metastatic foci of infection
• Clearance of bacteraemia
Starting date December 2014
Contact information Peter St Wecker, email: PStwecker@theravance.com; telephone: 650-808-6000
USA
Notes Estimated study completion date: April 2017




Study name Oral switch during treatment of leO-sided endocarditis due to multi-susceptible Streptococcus




Participants Male or female at least 18 years old
Inclusion criteria: several
NCT02701595 
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Exclusion criteria: several
Interventions Experimental: oral switch treatment. Oral switch to amoxicillin
Active comparator: conventional IV treatment according to European guidelines. Conventional IV
treatment of streptococci/enterococci infective disease (European guidelines 2015)
Outcomes Primary:
• Failure is a composite outcome defined by death from all causes and/or symptomatic embol-
ic events and/or unplanned valvular surgery and/or a microbiological relapse (with the primary
pathogen).
Secondary: several endpoints
Starting date 29 February 2016
Contact information Louis Bernard (L.BERNARD@chu-tours.fr)
Elodie Mousset (e.mousset@chu-tours.fr)
Notes Sponsor: University Hospital, Tours




Study name Oral switch during treatment of leO-sided endocarditis due to multi-susceptible Staphylococcus




Participants Male or female at least 18 years old
Inclusion criteria: several
Exclusion criteria: several
Interventions Experimental: oral switch treatment. Oral switch to combination levofloxacin and rifampicin
Active comparator: conventional IV treatment according to European guidelines. Conventional IV
treatment of staphylococci infective endocarditis (European guidelines 2015)
Outcomes Primary:
• Failure is a composite outcome defined by death from all causes and/or symptomatic embol-
ic events and/or unplanned valvular surgery and/or a microbiological relapse (with the primary
pathogen).
Secondary: several endpoints
Starting date 29 February 2016
Contact information Louis Bernard (L.BERNARD@chu-tours.fr)
NCT02701608 
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Elodie Mousset (e.mousset@chu-tours.fr)
Notes Sponsor: University Hospital, Tours




Study name A randomized, double-blind, multi-center study to establish the efficacy and safety of ceftobiprole
medocaril compared to daptomycin in the treatment of Staphylococcus aureus bacteremia, includ-
ing infective endocarditis
Methods Interventional (clinical trial), randomised, parallel assignment, quadruple masking (participant,
care provider, investigator, outcomes assessor)
Participants Inclusion criteria:
• Male or female ≥ 18 years of age
• Staphylococcus aureus bacteraemia, based on at least 1 positive blood culture obtained within
the 72 h prior to randomisation
• At least 2 of the following signs or symptoms of bacteraemia:
• fever ≥ 38 °C/100.4 °F
• white blood cell count > 10,000 or < 4000 cells/µL, or > 10% immature neutrophils (bands)
• tachycardia (heart rate > 90 beats per minute)
• hypotension (systolic blood pressure < 90 mmHg)
• At least 1 of the following:
• Staphylococcus aureus bacteraemia in patients undergoing chronic intermittent haemodialy-
sis or peritoneal dialysis
• Persistent Staphylococcus aureus bacteraemia
• Definite native-valve right-sided infective endocarditis by modified Duke's criteria
• Other forms of complicated Staphylococcus aureus bacteraemia
Exclusion criteria:
• Treatment with potentially effective (antistaphylococcal) systemic antibacterial treatment for
more than 48 h within the 7 days prior to randomisation. Exception: documented failure of blood-
stream clearance
• Bloodstream or non-bloodstream concomitant infections with gram-negative bacteria that are
known to be non-susceptible to either ceftobiprole or aztreonam
• LeO-sided infective endocarditis
• Prosthetic cardiac valves or valve support rings, cardiac pacemakers, automatic implantable car-
dioverter-defibrillator, or leO-ventricular assist devices
• Community- or hospital-acquired pneumonia
• Opportunistic infections within 30 days prior to randomisation, where the underlying cause of
these infections is still active
• Requirement for continuous renal-replacement therapy
• Women who are pregnant or nursing
• Other exclusion criteria may apply
Interventions Experimental: ceftobiprole medocaril (ceftobiprole medocaril 500 mg)
Active comparator: daptomycin (daptomycin 6 mg/kg, with or without aztreonam)
Outcomes Primary outcome measures:
NCT03138733 
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• Overall success at the PTE
Secondary outcome measures:
• All-cause mortality at the PTE visit
• Microbiological eradication at the PTE visit
• Overall success at the PTE visit
• Development of new metastatic foci or other complications of Staphylococcus aureus bacter-
aemia after day 7
• Time to Staphylococcus aureus bloodstream clearance
• Incidence, type, severity, and relationship to study medication of adverse events; and changes in
laboratory tests
• Ceftobiprole maximum plasma concentration
Ceftobiprole area under the concentration-time curve
Starting date 1 June 2018
Contact information Kamal Hamed, MD, MPH (+41 61 567 15 88) (kamal.hamed@basilea.com)
Marc Engelhardt, MD (+41 61 567 15 46) (marc.engelhardt@basilea.com)
Sponsors and collaborators: Basilea Pharmaceutica
Notes International, multicentre (56 sites)




Study name Efficacy and safety of dalbavancin compared to standard of care antibiotic therapy for the comple-
tion of treatment of patients with complicated bacteremia or infective endocarditis
Methods Interventional (clinical trial), randomised parallel assignment, single-masking (outcomes assessor),
treatment
Participants Male or female ≥ 18 years of age
Inclusion criteria:
• Diagnosis of complicated bacteraemia or infective endocarditis
• Gram-positive bacteraemia at screening with MSSA, MRSA, or streptococci
• Treatment with standard-of-care antibiotics for 72 h - 10 days
• Defervescence for at least 24 h and clearance of bacteraemia from screening pathogen
Exclusion criteria:
• Embolic events
• History of prosthetic valve surgery, cardiac device, or prosthetic joint
• LeO-sided endocarditis due to Staphylococcus aureus
• Large mobile vegetations (> 10 mm) on mitral valves
• Perivalvular abscess
• Several other exclusion criteria: see clinicaltrials.gov/ct2/show/NCT03148756 for details
Interventions Experimental: dalbavancin. Dalbavancin 1500 mg, IV administration over 30 minutes on days 1 and
8
NCT03148756 
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Active comparator: standard of care. Antibiotic consistent with standard of care, based on baseline
pathogen, for 4 to 6 weeks
Outcomes Primary outcome measures:
• Number of participants with clinical response at day 84 in the ITT population
Secondary outcome measures:
• Clinical outcome of success at day 42 in the ITT population
• Clinical outcome of success at day 42 in the clinically evaluable population
• Number of participants with day 84 mortality in the safety population
• Clinical outcome of success at day 84 in the clinically evaluable population
• Clinical outcome of success by pathogen at day 42 in the ITT population
• Note: total number of secondary outcome measures: 12. See clinicaltrials.gov/ct2/show/
NCT03148756 for details.
Starting date 12 May 2017
Contact information Sponsor: Allergan
Study Director: Urania Rappo, MD




Study name Short-course antibiotic regimen compared to conventional antibiotic treatment for Gram-positive
Cocci infective endocarditis: randomized clinical trial
Methods Randomised, parallel assignment, open-label
Phase IV




• Participants allocated to this group will receive a short course of antibiotic therapy for 2 weeks.
Control group:
• Those participants allocated to continue with standard parenteral treatment will maintain the
same antibiotic treatment for 4 to 6 weeks.
Outcomes Primary:
• Composite endpoint: all-cause mortality, unplanned cardiac surgery, symptomatic embolisms,
and relapses within 6 months after inclusion into the study, between participants with infective
endocarditis caused by gram-positive cocci receiving a short course of 2 weeks of antibiotic ther-
apy and those participants receiving conventional antibiotic therapy for 4 to 6 weeks
Secondary:
• Perceived quality of life: SF-12
NCT04222257 
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• Determination of functional performance according to the short performance physical battery
test
• Clinical complications: nosocomial infections, intravascular catheter-related infections
• Total hospital length of stay
Starting date 1 March 2020
Contact information Carmen Olmos Blanco, MD +0034-913303149
carmen.olmosblanco@gmail.com






Study name A phase 3 multicenter, randomized, open-label, clinical trial of telavancin versus standard intra-
venous therapy in the treatment of subjects with Staphylococcus aureus bacteremia including in-
fective endocarditis








• Telavancin, 7.5 mg/kg, IV in 100 to 250 mL over 60 (+/- 10) minutes, once every 24 hours for 2 to
6 weeks
Control group:
• Standard IV therapy, administered for 2 to 6 weeks: vancomycin (recommended dose of 15 mg/kg
IV every 12 hours); daptomycin (recommended dose of 6 mg/kg IV every 24 hours); antistaphylo-
coccal penicillin (i.e. nafcillin, oxacillin, or cloxacillin) recommended dose of 2 g IV every 4 hours or
12 g IV continuous infusion over 24 hours; or cefazolin (recommended dose of 2 g IV every 8 hours)
Outcomes Primary: clinical success or failure at test of cure
Secondary: reported as "not applicable"
Starting date 03 August 2016
Contact information Anna Carolina Coimbra (Rua da passagem, 123 / 6º andar, Botafogo 22290-030 Rio de Janeiro,
Brazil)
annacarolina.coimbra@incresearch.com
INC Research BR Serviços de Pesquisas Clínicas Ltda
RBR-3p8g7n 2016 
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Notes There is inconsistency regarding 'date of registration' (03 August 2016) and 'date of first enrol-
ment' (01 June 2015).
Status: discontinued (27 Feb 2018).
Source: https://adisinsight.springer.com/trials/700248032 (6 May 2020).
RBR-3p8g7n 2016  (Continued)
eGFR: estimated Glomerular Filtration Rate
ITT: intention-to-treat
IV: intravenous
MIC: minimum inhibitory concentration
MRSA: methicillin-resistant Staphylococcus aureus
MSSA: methicillin-susceptible Staphylococcus aureus
PTE: post-treatment evaluation




A P P E N D I C E S
Appendix 1. Types of infective endocarditis
• According to localisation of infection and presence or absence of intracardiac material (leO-sided native valve, leO-sided prosthetic
valve, right-sided and device-related (permanent pacemaker or cardioverter-defibrillator)).
• According to the mode of acquisition (healthcare associated (nosocomial and non-nosocomial), community-acquired, and intravenous
drug abusers).
• Active (infective endocarditis with persistent fever, and positive blood culture or active inflammatory morphology found at surgery or
person still under antibiotic therapy or histopathological evidence of active infective endocarditis).
• Recurrent (relapse or reinfection).
From Habib 2019.
Appendix 2. Clinical presentation of infective endocarditis
Infective endocarditis should be suspected in the following situations.
• New regurgitant heart murmur.
• Embolic events of unknown origin.
• Sepsis of unknown origin (especially if it is associated with an organism recognised as causing infective endocarditis).
• Fever: the most frequent sign of infective endocarditis. Fever may be absent in older people, aOer antibiotic pre-treatment, in
immunocompromised people, and in infective endocarditis involving less virulent or atypical organisms.
Infective endocarditis should be suspected if fever is associated with the following.
• Intracardiac prosthetic material (e.g. prosthetic valve, pacemaker or implantable defibrillator, surgical ba&le/conduit).
• Previous history of infective endocarditis.
• Known valvular or congenital heart disease.
• Other predisposition for infective endocarditis (e.g. immunocompromised state, intravenous drug abusers).
• Recent intervention with associated bacteraemia.
• Evidence of congestive heart failure.
• New conduction disturbance.
• Positive blood cultures with typical infective endocarditis causative organism or positive serology for chronic Q fever (microbiological
findings may precede cardiac manifestations).
• Vascular or immunological phenomena: embolic event, Roth spots, splinter haemorrhages, Janeway lesions, Osler's nodes.
• Focal or non-specific neurological symptoms and signs.
• Evidence of pulmonary embolism/infiltration (right-sided infective endocarditis).
• Peripheral abscesses (renal, splenic, cerebral, vertebral) of unknown cause.
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From Habib 2019.
Appendix 3. Antibiotic therapy for the treatment of infective endocarditis: recommended dosages of the main
antibiotics
• Crystalline penicillin G 12 to 18 million U/24 h IV either continuously or in 4 or 6 equally divided doses.
• Ampicillin sodium 12 g/24 h IV in 6 equally divided doses.
• Flucloxacillin 12 g/24 h IV in 6 equally divided doses.
• Nafcillin or oxacillin 12 g/24 h IV in 6 equally divided doses.
• CeOriaxone 2 g/24 h IV/IM in 1 dose.
• Vancomycin 30 mg/kg per 24 h IV in 2 equally divided doses.
• Teicoplanin 10 mg/kg per 24 h.
• Gentamicin 3 mg/kg per 24 h IV/IM in 1 dose.
• Daptomycin 6 mg/kg per 24 h.
• Levofloxacin 500 mg/daily either IV or orally.
Abbreviations: IM: intramuscular; IV: intravenous U: unit
Sources: Baddour 2015; FINLEVO Trial 2006..
A description of the various classes of antibiotics and their adverse reactions follows below.
Clinical pharmacology and microbiological spectrum
Many antimicrobial drugs have been used alone or in combination in the treatment of infective endocarditis (Vinh 2016). They include
beta-lactam antibiotics, aminoglycosides, glycopeptides, oxazolidinones, and complex macrocyclic antibiotics (Drees 2006; Frank 2009).
• Beta-lactam antibiotics: includes penicillins, cephalosporins, and carbapenems (Petri 2001a). The penicillins consist of penicillins
G and V, which are highly active against susceptible gram-positive cocci, and ampicillin and other agents with an improved gram-
negative spectrum. This group also includes the cephalosporin antibiotics, which are classified by generation: first-generation agents
with excellent gram-positive and modest gram-negative activity; second-generation agents with somewhat better activity against
gram-negative organisms and some have additional anti-anaerobe activity; third-generation agents have activity against gram-positive
organisms and more activity against the Enterobacteriaceae, with a subset active against Pseudomonas aeruginosa; and fourth-
generation agents encompass the antimicrobial spectrum of all the third-generation agents but have increased stability to hydrolysis
by inducible chromosomal beta-lactamases (Petri 2001a).
• Aminoglycosides: gentamicin is the most studied drug of this pharmacological antibiotic class (Chambers 2001a), and was once widely
used as a primary agent for treating gram-negative infections. However, because of their toxicity and the availability of newer e&ective
agents, systemic aminoglycosides have been primarily relegated to a role as companion drugs, either to broaden coverage against
gram-negative aerobic bacilli, or to provide synergistic e&ects against gram-positive cocci or certain gram-negative bacilli (Chen 2009).
Aminoglycosides are poorly absorbed orally, and the excretion of aminoglycosides is primarily by glomerular filtration; clearance is
decreased with renal insu&iciency, but increased in children and pregnant women (Chen 2009). In addition to gentamicin, amikacin and
streptomycin are aminoglycosides that have been used to treat infective endocarditis.
• Glycopeptides: includes vancomycin and teicoplanin, which have been widely used for treating serious gram-positive infections,
particularly those involving methicillin-resistant Staphylococcus aureus (Nailor 2009).
• Oxazolidinones: linezolid is a synthetic class of antimicrobial agent. Linezolid has both parenteral and oral preparations with 100%
bioavailability, and penetrates well into tissues (Dryden 2011). The antimicrobial spectrum of the oxazolidinedione is similar to that
of vancomycin, with activity against most gram-positive organisms, including methicillin-resistant S aureus and penicillin-resistant
pneumococci (Leach 2011; Muñoz 2007; Nailor 2009).
• Complex macrocyclic antibiotics (rifamycins): rifampicin is highly active against both coagulase-positive and -negative staphylococci
and other gram-positive cocci, such as Streptococcus pyogenes and Streptococcus pneumoniae (Chen 2009; Petri 2001b). Enterococci
are only moderately susceptible. Among gram-negative organisms, Neisseria meningitidis, Neisseria gonorrhoeae, and Hemophilus
influenzae are the most susceptible. Rifampicin is well absorbed when given orally. An intravenous preparation is available when the
oral route cannot be used. It penetrates well into body fluids, achieving therapeutic levels in saliva, bile, bone, pleural fluid, prostate,
and cerebrospinal fluid. Moreover, rifampicin readily enters phagocytic cells and can kill micro-organisms in the cells (Chen 2009).
• Lipopeptide antibiotics (daptomycin): an antibiotic with bactericidal activity against S aureus bacteraemia and endocarditis, and
infections caused by Enterococcus spp., especially if vancomycin-resistant (Warren 2008). There are reports of an increasing of
daptomycin non-susceptibility in S aureus, Enterococcus faecium, and Enterococcus faecalis (Humphries 2013).
• Fluoroquinolone (levofloxacin): a synthetic antimicrobial agent of third-generation fluoroquinolone that is quickly absorbed by oral
administration (Leyva 2008; Liu 2010). This property is important because the intravenous formulation can be changed to oral route.
This drug has a broad-spectrum antibacterial profile (Anderson 2008).
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Antibiotic adverse reactions
The major antibiotic adverse reactions associated with the main antimicrobial drugs for treating infective endocarditis have been widely
described (Granowitz 2008). Briefly, untoward reactions of these drugs are as follows.
• Beta-lactam antibiotics: although this group of antibiotics commonly causes drug hypersensitivity reactions (Chambers 2001b;
Torres 2010), beta-lactams are generally safe (Lagace-Wiens 2012; Petri 2001a), and serious adverse events are rare and allergy is
overdiagnosed (Lagace-Wiens 2012). One publication suggests that amoxicillin given as endocarditis prophylaxis is associated with a
very low rate of adverse events (Thornhill 2015).
• Aminoglycosides: gentamicin: the major adverse e&ects of the aminoglycosides are nephrotoxicity and oto-vestibular toxicity
(Chen 2009). Furthermore, aminoglycosides can cause neuromuscular blockade due to interference with neurotransmission at the
neuromuscular junction (Chen 2009; Cosgrove 2009).
• Glycopeptides: vancomycin: there are three major adverse events associated with this drug. First, the 'red man' syndrome is a non-
immunologically mediated histamine release associated with rapid infusion of vancomycin. Clinical signs and symptoms include
pruritus, erythema, and flushing of the upper torso, angio-oedema, and occasionally, hypotension (Nailor 2009). Second, nephrotoxicity
is well described, but rare when vancomycin is used alone and at conventional dosages (e.g. 1 g every 12 hours) (Nailor 2009). The risk
increases in people who are critically ill and on vasopressor support or when used with concomitant nephrotoxic agents, or both; who
have deranged renal function at baseline; who are undergoing prolonged duration of therapy; or who are obese (Gupta 2011; Wong-
Beringer 2011). Third, deafness may occur, usually preceded by tinnitus and high-tone hearing loss (Nailor 2009).
• Oxazolidinones: linezolid: the major adverse events associated with the use of this drug include hepatic dysfunction (Gould 2011),
peripheral neuropathies (Gould 2011; Vinh 2016), with or without optic neuropathy in people receiving therapy for more than 28 days
(Gould 2011), haematological abnormalities (anaemia and thrombocytopenia) (Gould 2011), gastrointestinal disturbances (Gould 2011;
Vinh 2016), and lactic acidosis, generally in people with numerous comorbidities, such as thiamine deficiency or cirrhosis (Gould 2011).
• Complex macrocyclic antibiotics: rifampicin: the administration of this drug frequently results in urine and sweat developing an
orange tinge; soO contact lenses may be stained. An influenza-like syndrome can occur in up to 5% of people who have had prolonged
intermittent use of rifampicin. Rash and gastrointestinal adverse e&ects (e.g. nausea, vomiting, diarrhoea, heartburn) may occur in up
to 5% of people. Abnormal liver function tests are common, but frank hepatitis is uncommon (< 1%) (Chen 2009).
• Lipopeptide antibiotics: daptomycin: Shrestha and colleagues have reported that people receiving daptomycin at home have fewer
antimicrobial adverse events than similar people receiving vancomycin (Shrestha 2014). One meta-analysis assessing the safety and
e&icacy of daptomycin versus other antibiotics for skin and soO-tissue infections showed higher creatine phosphokinase elevation in
the daptomycin group than in the control group (Wang 2014), as reported by Falagas and colleagues in people with endocarditis and
treated with daptomycin (Falagas 2007).
• Fluoroquinolone: levofloxacin: this drug is relatively well tolerated, with low rates of clinically important adverse events such as
central nervous system toxicity (headache and dizziness), cardiovascular toxicity (QT interval prolongation), and metabolism glucose
disruption (Liu 2010).
How the intervention might work
Appropriate antibiotic treatment is important to control local infection, eradicate the organisms from the vegetations, and reduce the risk
of complications such as septic embolisation (Baddour 2015).
The pharmacodynamics of the most frequent antimicrobial drugs used for treating infective endocarditis include the following.
• Beta-lactam antibiotics: the beta-lactam antibiotics share a common mechanism of action, i.e. inhibition of synthesis of the bacterial
peptidoglycan cell wall (Petri 2001a).
• Aminoglycosides: gentamicin is the most studied aminoglycoside, and acts in part by impairing bacterial protein synthesis through
irreversible binding to the 30S subunit of the bacterial ribosome (Chen 2009).
• Glycopeptides: vancomycin exhibits concentration-independent bactericidal activity by the inhibition of bacterial cell wall synthesis.
Vancomycin requires actively growing bacteria to exert its e&ect (Nailor 2009).
• Oxazolidinones: linezolid exerts its e&ect early in protein synthesis by inhibiting the initiation complex at the 30S ribosome (Nailor
2009; Vinh 2016).
• Complex macrocyclic antibiotics: rifampicin acts by inhibiting deoxyribonucleic acid-dependent ribonucleic acid polymerase, aOer
binding to the beta subunit of the enzyme. This interaction interferes with protein synthesis by preventing chain initiation (Chen 2009).
• Lipopeptide antibiotics: daptomycin a&ects the membrane of the micro-organism through a calcium-dependent dissipation of
membrane potential that leads to the release of intracellular ions from the cell and bacteria death (Vilhena 2012).
• Fluoroquinolone: levofloxacin acts by inhibition of deoxyribonucleic acid gyrase or topoisomerase IV (Leyva 2008).
Appendix 4. Search strategies
CENTRAL
#1 MeSH descriptor: [Endocarditis] explode all trees
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#2 endocarditi*
#3 (infect* near/2 endocard*)
#4 #1 or #2 or #3
#5 MeSH descriptor: [Anti-Infective Agents] explode all trees
#6 ((antimycobacterial or (anti next mycobacterial) or antibacterial or (anti next bacterial) or antibiotic*) near/2 (drug* or agent* or
treatment* or medicat* or therap*))
#7 (((anti next infect*) or antiinfect* or antimicrobial or (anti next microbial)) near/2 (drug* or agent* or treatment* or medicat* or therap*))
#8 bacteriocid*
#9 ampicillin or amcill or ukapen or polycillin or omnipen or aminobenzylpenicillin or (aminobenzyl next penicillin) or pentrexyl or
amoxicillin or azlocillin
#10 mezlocillin or piperacillin or pivampicillin or talampicillin or aminopenicillin* or (Penicillin next g) or penilevel or pekamin or penibiot
or ursopen or van-pen-g
#11 pfizerpen or sodiopen or benpen or peniroger or or-pen or pengesod or (sodium next penicillin) or parcillin or unicilina or
(benzylpenicillin next potassium)
#12 sodipen or crystapen or coliriocilina or benzylpenicillin or Sulbenicillin or Carbenicillin or flucloxacillin or floxacillin or
fluorochloroxacillin or cefazolin or cephazolin or cephamezine
#13 cefamedin or totacef or cefamezine or gramaxin or ancef or kefzol or cephalosporin* or ceOriaxon* or terbac or rocefalin or longacef
or rocephine or lendacin or rocephin
#14 cefaxona or ceOrex or longaceph or rocefin or tacex or benaxona
#15 MeSH descriptor: [Aminoglycosides] explode all trees
#16 gentam?cin* or gentavet or genticin or garamycin or gentacycol or gmyticin or (g next myticin) or aminoglycoside* or vancom?cin* or
vanco-saar or (vanco next azupharma)
#17 diatracin or (vancocin next hcl) or ab-vancomycin or vanco-cell or vancocin* or linezolid* or benemycin or rimactane or tubocin or
rifampicin or rimactan or rifadin or rifampin
#18 MeSH descriptor: [Glycopeptides] explode all trees
#19 Bleomycin or Peptidoglycan or Ristocetin or Teicoplanin
#20 MeSH descriptor: [beta-Lactams] this term only
#21 (beta-lactam* near/2 antibiot*) or betalactam
#22 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21




3. (infect* adj2 endocard*).tw.
4. or/1-3
5. exp Anti-Infective Agents/
6. ((antimycobacterial or anti mycobacterial or antibacterial or anti bacterial or antibiotic*) adj (drug* or agent* or treatment* or medicat*
or therap*)).tw.
7. ((anti infect* or antiinfect* or antimicrobial or anti microbial) adj (drug* or agent* or treatment* or medicat* or therap*)).tw.
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78. gentacycol.tw.
























103. (beta-lactam* adj2 antibiot*).tw.
104. betalactam.tw.
105. or/5-104
106. 4 and 105
107. randomized controlled trial.pt.
108. controlled clinical trial.pt.
109. randomized.ab.
110. placebo.ab.
111. clinical trials as topic.sh.
112. randomly.ab.
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113. trial.ti.
114. 107 or 108 or 109 or 110 or 111 or 112 or 113
115. exp animals/ not humans.sh.
116. 114 not 115




3. (infect* adj2 endocard*).tw.
4. or/1-3
5. exp antiinfective agent/
6. ((antimycobacterial or anti mycobacterial or antibacterial or anti bacterial or antibiotic*) adj (drug* or agent* or treatment* or medicat*
or therap*)).tw.
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103. (beta-lactam* adj2 antibiot*).tw.
104. betalactam.tw.
105. or/5-104







113. (doubl$ adj blind$).tw.





119. double blind procedure/
120. randomized controlled trial/
121. single blind procedure/
122. 107 or 108 or 109 or 110 or 111 or 112 or 113 or 114 or 115 or 116 or 117 or 118 or 119 or 120 or 121
123. (animal/ or nonhuman/) not human/
124. 122 not 123
125. 106 and 124
126. limit 125 to embase
LILACS
"antibiotics" [Subject descriptor] or (antibiotic$ OR antiinfect$ OR anti-infect$ OR antibacter$ OR anti-bacter$) [Words] and (endocarditis)
or "endocarditis" [Words]
CINAHL
S51 S32 AND S50
S50 S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49
S49 cross-over*
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S48 crossover*
S47 volunteer*







S39 (doubl* N1 mask*)
S38 (singl* N1 mask*)
S37 (doubl* N1 blind*)
S36 (singl* N1 blind)
S35 (clinic* N1 trial?)
S34 PT clinical trial
S33 (MH "Clinical Trials")
S32 S4 and S31
S31 S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22 or S23 or S24 or
S25 or S26 or S27 or S28 or S29 or S30
S30 AB (gentam?cin* or gentavet or genticin or garamycin or gentacycol or gmyticin or "g myticin" or aminoglycoside* or vancom?cin* or
vanco-saar or "vanco azupharma")
S29 TI (gentam?cin* or gentavet or genticin or garamycin or gentacycol or gmyticin or "g myticin" or aminoglycoside* or vancom?cin* or
vanco-saar or "vanco azupharma")
S28 AB ((beta-lactam* N2 antibiot*) or betalactam)
S27 TI ((beta-lactam* N2 antibiot*) or betalactam)
S26 AB (Bleomycin or Peptidoglycan or Ristocetin or Teicoplanin or glycopeptid*)
S25 TI (Bleomycin or Peptidoglycan or Ristocetin or Teicoplanin or glycopeptid*)
S24 AB (diatracin or "vancocin hcl" or ab-vancomycin or vanco-cell or vancocin* or linezolid* or benemycin or rimactane or tubocin or
rifampicin or rimactan or rifadin or rifampin)
S23 TI (diatracin or "vancocin hcl" or ab-vancomycin or vanco-cell or vancocin* or linezolid* or benemycin or rimactane or tubocin or
rifampicin or rimactan or rifadin or rifampin)
S22 (MH "Aminoglycosides+")
S21 TI (cefaxona or ceOrex or longaceph or rocefin or tacex or benaxona) or AB (cefaxona or ceOrex or longaceph or rocefin or tacex or
benaxona)
S20 AB (cefamedin or totacef or cefamezine or gramaxin or ancef or kefzol or cephalosporin* or ceOriaxon* or terbac or rocefalin or longacef
or rocephine or lendacin or rocephin)
S19 TI (cefamedin or totacef or cefamezine or gramaxin or ancef or kefzol or cephalosporin* or ceOriaxon* or terbac or rocefalin or longacef
or rocephine or lendacin or rocephin)
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S18 AB (sodipen or crystapen or coliriocilina or benzylpenicillin or Sulbenicillin or Carbenicillin or flucloxacillin or floxacillin or
fluorochloroxacillin or cefazolin or cephazolin or cephamezine)
S17 TI (sodipen or crystapen or coliriocilina or benzylpenicillin or Sulbenicillin or Carbenicillin or flucloxacillin or floxacillin or
fluorochloroxacillin or cefazolin or cephazolin or cephamezine)
S16 AB (pfizerpen or sodiopen or benpen or peniroger or or-pen or pengesod or "sodium penicillin" or parcillin or unicilina or
"benzylpenicillin potassium")
S15 TI (pfizerpen or sodiopen or benpen or peniroger or or-pen or pengesod or "sodium penicillin" or parcillin or unicilina or
"benzylpenicillin potassium")
S14 AB (mezlocillin or piperacillin or pivampicillin or talampicillin or aminopenicillin* or "Penicillin g" or penilevel or pekamin or penibiot
or ursopen or van-pen-g)
S13 TI (mezlocillin or piperacillin or pivampicillin or talampicillin or aminopenicillin* or "Penicillin g" or penilevel or pekamin or penibiot
or ursopen or van-pen-g)
S12 AB (ampicillin or amcill or ukapen or polycillin or omnipen or aminobenzylpenicillin or "aminobenzyl penicillin" or pentrexyl or
amoxicillin or azlocillin)
S11 TI (ampicillin or amcill or ukapen or polycillin or omnipen or aminobenzylpenicillin or "aminobenzyl penicillin" or pentrexyl or
amoxicillin or azlocillin)
S10 TI bacteriocid* or AB bacteriocid*
S9 AB (("anti infect*" or antiinfect* or antimicrobial or "anti microbial") N2 (drug* or agent* or treatment* or medicat* or therap*))
S8 TI (("anti infect*" or antiinfect* or antimicrobial or "anti microbial") N2 (drug* or agent* or treatment* or medicat* or therap*))
S7 AB ((antimycobacterial or "anti mycobacterial" or antibacterial or "anti bacterial" or antibiotic*) N2 (drug* or agent* or treatment* or
medicat* or therap*))
S6 TI ((antimycobacterial or "anti mycobacterial" or antibacterial or "anti bacterial" or antibiotic*) N2 (drug* or agent* or treatment* or
medicat* or therap*))
S5 (MH "Antiinfective Agents+")
S4 S1 or S2 or S3
S3 TI (infect* N2 endocard*) or AB (infect* N2 endocard*)
S2 TI endocarditi* or AB endocarditi*
S1 (MH "Endocarditis+")
Web of Science
#14 #13 AND #12
#13 TS=(random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*)
#12 #11 AND #1
#11 #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2
#10 TS=(Bleomycin or Peptidoglycan or Ristocetin or Teicoplanin or (beta-lactam* NEAR/2 antibiot*) or betalactam)
#9 TS=(cefaxona or ceOrex or longaceph or rocefin or tacex or benaxona or Glycopeptide*)
#8 TS=(cefamedin or totacef or cefamezine or gramaxin or ancef or kefzol or cephalosporin* or ceOriaxon* or terbac or rocefalin or longacef
or rocephine or lendacin or rocephin)
#7 TS=(sodipen or crystapen or coliriocilina or benzylpenicillin or Sulbenicillin or Carbenicillin or flucloxacillin or floxacillin or
fluorochloroxacillin or cefazolin or cephazolin or cephamezine)
#6 TS=(pfizerpen or sodiopen or benpen or peniroger or or-pen or pengesod or "sodium penicillin" or parcillin or unicilina or
"benzylpenicillin potassium")
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#5 TS=(mezlocillin or piperacillin or pivampicillin or talampicillin or aminopenicillin* or "Penicillin g" or penilevel or pekamin or penibiot
or ursopen or van- pen-g)
#4 TS=(bacteriocid* or ampicillin or amcill or ukapen or polycillin or omnipen or aminobenzylpenicillin or "aminobenzyl penicillin" or
pentrexyl or amoxicillin or azlocillin)
#3 TS=(("anti infect*" or antiinfect* or antimicrobial or "anti microbial") NEAR/2 (drug* or agent* or treatment* or medicat* or therap*))
#2 TS=((antibiotic* or antimycobacterial or "anti mycobacterial" or antibacterial or "anti bacterial") NEAR/2 (drug* or agent* or treatment*
or medicat* or therap*))
#1 TS=endocard*
clinicaltrials.gov
infective endocarditis plus randomized and recruiting OR not yet recruiting
International Clinical Trials Registry Platform Search Portal
infective endocarditis AND randomized
ISRCTN registry
infective endocarditis AND randomized
Appendix 5. Assessment of risk of bias in included studies
Generation of allocation sequence (checking for possible selection bias)
We described for each included study the method used to generate the allocation sequence in su&icient detail to allow an assessment of
whether it should produce comparable groups.
We assessed the method as:
• low risk (any truly random process, e.g. random number table; computer random number generator);
• high risk (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);
• unclear, if the trial was described as randomised, but the method used for the allocation sequence generation was not described.
Allocation concealment (checking for possible selection bias)
We described for each included study the method used to conceal the allocation sequence in su&icient detail to determine whether
intervention allocation could have been foreseen in advance of, or during recruitment, or changed aOer assignment.
We assessed the methods as:
• low risk (e.g. telephone or central randomisation; consecutively numbered, sealed, opaque envelopes);
• high risk (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);
• unclear, if the trial was described as randomised, but the method used to conceal the allocation was not described.
Blinding or masking (checking for possible performance bias)
We described for each included study the methods used, if any, to blind study participants and personnel from the knowledge of which
intervention a participant received. We judged studies to be at low risk of bias if they were blinded, or if we judged that the lack of blinding
could not have a&ected the results. We assessed blinding separately for di&erent outcomes or classes of outcomes.
We assessed the methods as:
• low risk, high risk, or unclear risk for participants;
• low risk, high risk, or unclear risk for personnel;
• low risk, high risk, or unclear risk for outcome assessors.
Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations)
• Low risk (any one of the following): no missing outcome data; reasons for missing outcome data unlikely to be related to true outcome
(for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups,
with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared
with observed event risk not enough to have a clinically relevant impact on the intervention e&ect estimate; for continuous outcome
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data, plausible e&ect size (di&erence in means or standardised di&erence in means) amongst missing outcomes not enough to have a
clinically relevant impact on observed e&ect size; missing data were imputed using appropriate methods.
• High risk (any one of the following): reason for missing outcome data likely to be related to true outcome, with either an imbalance in
numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk enough to induce clinically relevant bias in intervention e&ect estimate; for continuous outcome
data, plausible e&ect size (di&erence in means or standardised di&erence in means) amongst missing outcomes enough to induce
clinically relevant bias in observed e&ect size; 'as-treated' analysis done with substantial departure of the intervention received from
that assigned at randomisation; potentially inappropriate application of simple imputation.
• Unclear risk (any one of the following): insu&icient reporting of attrition/exclusions to permit judgement of 'low risk' or 'high risk' (e.g.
number randomised not stated, no reasons for missing data provided); the study did not address this outcome.
Selective reporting bias (reporting bias due to selective outcome reporting)
We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk (any one of the following): the study protocol was available, and all of the study's prespecified (primary and secondary)
outcomes that were of interest in the review were reported in the prespecified way, or the study protocol was not available but it was
clear that the published reports included all expected outcomes, including those that were prespecified (convincing text of this nature
may be uncommon);
• high risk (any one of the following): not all of the study's prespecified primary outcomes were reported; one or more primary outcomes
were reported using measurements, analysis methods, or subsets of the data (e.g. subscales) that were not prespecified; one or more
reported primary outcomes were not prespecified (unless clear justification for their reporting was provided, such as an unexpected
adverse e&ect); one or more outcomes of interest in the review were reported incompletely so that they could not be entered in a meta-
analysis; the study report did not include results for a key outcome that would be expected to have been reported for such a study;
• unclear risk: insu&icient information to permit judgement of 'low risk' or 'high risk'.
Free of other bias (bias due to problems not covered elsewhere)
We described for each included study any important concerns we had about other possible sources of bias (sponsorship bias, confirmation
bias, bias of the presentation data, etc.).
• Low risk: the trial appears to be free of other components that could put it at risk of bias.
• High risk: there are other factors in the trial that could put it at risk of bias (e.g. no sample size calculation made).
• Unclear risk: the trial may or may not be free of other components that could put it at risk of bias.
Overall risk of bias
We made explicit judgements about whether studies were at high risk of bias, according to the criteria described in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). We assessed the likely magnitude and direction of the bias and whether we
considered it was likely to impact on the findings.
Appendix 6. Oral regimens recommended in POET 2019
Penicillin and methicillin-sensitive Staphylococcus aureus and coagulase-negative staphylococci
• Amoxicillin 1 g x 4 and fusidic acid 0.75 g x 2
• Amoxicillin 1 g x 4 and rifampicin 0.6 g x 2
• Linezolid 0.6 g x 2 and fusidic acid 0.75 g x 2
• Linezolid 0.6 g x 2 and rifampicin 0.6 g x 2
Methicillin-sensitive Staphylococcus aureus and coagulase-negative staphylococci
• Dicloxacillin 1 g x 4 and fusidic acid 0.75 g x 2
• Dicloxacillin 1 g x 4 and rifampicin 0.6 g x 2
• Linezolid 0.6 g x 2 and fusidic acid 0.75 g x 2
• Linezolid 0.6 g x 2 and rifampicin 0.6 g x 2
Methicillin-resistant coagulase-negative staphylococci
• Linezolid 0.6 g x 2 and fusidic acid
• Linezolid 0.6 g x 2 and rifampicin 0.6 g x 2
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Enterococcus faecalis
• Amoxicillin 1 g x 4 and rifampicin 0.6 g x 2
• Amoxicillin 1 g x 4 and moxifloxacin 0.4 g x 1
• Linezolid 0.6 g x 2 and rifampicin 0.6 g x 2
• Linezolid 0.6 g x 2 and moxifloxacin 0.4 g x 1
Streptococci with a minimal inhibitory concentration for penicillin of < 1 mg/L
• Amoxicillin 1 g x 4 and rifampicin 0.6 g x 2
• Linezolid 0.6 g x 2 and rifampicin 0.6 g x 2
• Linezolid 0.6 g x 2 and moxifloxacin 0.4 g x 1
Streptococci with a minimal inhibitory concentration for penicillin of ≥ 1 mg/L
• Linezolid 0.6 g x 2 and rifampicin 0.6 g x 2
• Moxifloxacin 0.4 g x 1 and rifampicin 0.6 g x 2
• Moxifloxacin 0.4 g x 1 and clindamycin 0.6 g x 3
Source: POET 2019 (Supplementary Appendix).
Appendix 7. Oral antibiotic regimens in POET 2019
 
Micro-organism Regimens Frequency (%)
Dicloxacillin and rifampicin 33Staphylococcus aureus
Amoxicillin and rifampicin 29
Amoxicillin and moxifloxacin 47
Amoxicillin and linezolid 25
Amoxicillin and rifampicin 12
Enterococcus faecalis
Moxifloxacin and linezolid 10
Amoxicillin and rifampicin 52Streptococci
Amoxicillin and moxifloxacin 13
Fusidic acid and linezolid 38Coagulase-negative staphy-
lococci
Rifampicin and linezolid 31
Source: POET 2019 (Supplementary Appendix)
 
 
W H A T ' S   N E W
 
Date Event Description
5 February 2020 New citation required but conclusions
have not changed
Conclusion: This first update confirms the findings of the original
version: current evidence does not support or reject any regimen
of antibiotic therapy for the treatment of infective endocarditis.
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Date Event Description
6 January 2020 New search has been performed This update is based on a search from 6 January 2020 and in-
cludes two new randomised controlled trials. The review has a
total of six included trials.
 
H I S T O R Y
Protocol first published: Issue 5, 2012
Review first published: Issue 4, 2016
C O N T R I B U T I O N S   O F   A U T H O R S
Arturo Martí-Carvajal is the lead author of the protocol and review, and acts as guarantor of the review.
Mark Dayer reviewed and contributed to the manuscript.
Lucieni Oliveira Conterno contributed to the review conception and design; screened the studies for inclusion; assessed the risk of bias;
interpreted the results providing a clinical perspective; revised and commented on the draO; and approved the final version.
Alejandro González Garay and Cristina Martí-Amarista checked the search results and data, and contributed to the manuscript.
D E C L A R A T I O N S   O F   I N T E R E S T
Arturo Martí-Carvajal: in 2004 Arturo Martí-Carvajal was employed by Eli Lilly to run a four-hour workshop on 'How to critically appraise
clinical trials on osteoporosis and how to teach this'. This activity was not related to his work with Cochrane or any Cochrane Review. In
2007, Arturo Martí-Carvajal was employed by Merck to run a four-hour workshop on 'How to critically appraise clinical trials and how to
teach this'. This activity was not related to his work with Cochrane or any Cochrane Review.
Mark Dayer is currently undertaking clinical trials, sponsored by Novartis, in the field of heart failure. He has received no direct funding from
Novartis since 2008, when the company sponsored his attendance at the European Society of Cardiology. Novartis is the manufacturer of
daptomycin. In 2015, Dr Dayer received educational sponsorship from Bayer. He received advisory board fees from Res-Med (2014 to 2015),
Daiichi-Sankyo (2015), and St Jude (2015 to 2016). Between 2007 and 2015, Dr Dayer also received educational sponsorship/speaker fees
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
• We added:
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• lipopeptide antibiotics (daptomycin) into the Background and Types of interventions due to the inclusion of a trial assessing that
drug (Fowler 2006);
• quinolone antibiotics (levofloxacin) into the Background and Types of interventions due to the inclusion of a trial assessing that
drug (FINLEVO Trial 2006).
• We changed:
• the initial review question, which was to assess the e&ect of antibiotic treatment versus no antibiotic treatment, as no suitable studies
were identified;
• the number of authors who extracted data. We had planned for three review authors to independently extract data, but only two
extracted the data, as only two review authors were available at the time of the data extraction;
• the presentation of data. We added a 'Summary of findings' table and GRADE assessments;
• the search strategy. We did not search the Scientific Electronic Library Online (SciELO) because of more recent concerns over the
quality of some open access studies;
• we removed the following sentence: "...we will consider there to be substantial statistical heterogeneity if the I2 statistic is greater
than 50% (Higgins 2011), and will explore this by pre-specified subgroup analysis". We did this to adapt this Cochrane Review to
statistical issues and common analysis queries of the Cochrane Heart Group;
• we removed those studies that were not randomised controlled trials from the Excluded studies section.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Anti-Bacterial Agents  [adverse e&ects]  [*therapeutic use];  Endocarditis, Bacterial  [*drug therapy]  [microbiology]  [mortality];
  Fosfomycin  [adverse e&ects]  [therapeutic use];  Imipenem  [adverse e&ects]  [therapeutic use];  Levofloxacin  [adverse e&ects]




A comparison of dierent antibiotic regimens for the treatment of infective endocarditis (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
86
